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Platelet-derived growth factor receptor α (PDGFRα) is a tyrosine kinase receptor that plays a role 
in cell survival, proliferation, and differentiation, and is involved in liver development, 
regeneration and chronic liver injury states such as hepatic fibrosis and cirrhosis. Hepatic stellate 
cells (HSCs) are the primary mediators of hepatic fibrosis through their activation from a quiescent 
state in response to the presence of pro-fibrotic growth factors such as PDGFs. Proliferation and 
migration are key outcomes of this transition, facilitating collagen deposition and migration of 
activated HSCs to sites of liver injury. We confirm the upregulation of PDGFRα in pericentral 
hepatocytes in CCl4-induced liver injury as well as HSCs/myofibroblasts in carbon tetrachloride 
(CCl4), bile duct ligation (BDL), and 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-
induced liver injury. After ruling out a significant contribution of hepatocyte PDGFRα in hepatic 
fibrosis using Alb-Cre and FoxA3-Cre Pdgfra-/- animals, we examine PDGFRα signaling in 
primary human HSCs (HHSteCs) in combination with human PDGFRα–specific inhibitory 
monoclonal antibody Olaratumab to test the hypothesis that PDGFRα signaling in HSCs promotes 
hepatic fibrosis. Olaratumab-mediated PDGFRα inhibition resulted in decreased HHSteC 
proliferation and motility, while lacking an effect on transcriptional expression of fibrosis-
associated genes. Furthermore, Olaratumab reduced activation of downstream signaling effectors 
involved in proliferation and motility including Akt, mTOR, Erk1/2, FAK, and p38 MAPK 
suggesting that PDGFRα contributes to mitogenesis and actin reorganization through diverse 
downstream mediators. This evidence was corroborated with findings that HSC-specific Lrat-Cre 
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Pdgfra-/- mice showed reduced CCl4-induced fibrosis after 4 weeks (early fibrosis) followed by 
reduced ALT/AST levels at 8 weeks (advanced fibrosis). This was accompanied by increased 
macrophage infiltration and increased TUNEL-positive HSCs/myofibroblasts concomitant with a 
decrease in TUNEL-positive hepatocytes, suggesting that PDGFRα loss in HSCs may promote 
injury resolution in advanced fibrosis by limiting HSC/myofibroblast survival. These findings 
support a distinct pro-fibrotic role of PDGFRα in HSCs during chronic liver injury in both mice 
and human primary cells and provides an important pre-clinical foundation for the future testing 
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1.0  BACKGROUND: CHRONIC LIVER INJURY AND ROLE OF PDGFRα IN 
LIVER PATHOPHYSIOLOGY 
1.1 OVERVIEW OF CHRONIC LIVER INJURY 
Chronic liver disease is a significant cause of morbidity worldwide. In the U.S. alone, around 5.5 
million Americans suffer from hepatic fibrosis and cirrhosis 1. Hepatic fibrosis, similar to fibrotic 
diseases in other solid tissues, is primarily a wound healing response in which myofibroblasts 
stemming from resident tissue fibroblasts propagate the accumulation and qualitative changes to 
the extracellular matrix (ECM). The etiologies of hepatic fibrosis are wide ranging and many 
different forms of repeated injury to the liver can result in the common outcome of hepatic fibrosis. 
Some of the most common types of chronic liver injury leading to cirrhosis in developed countries 
include alcoholic liver disease, cholestatic liver disease (including primary/secondary biliary 
cirrhosis, biliary atresia/neonatal hepatitis, congenital biliary cysts, and neonatal hepatitis), chronic 
viral hepatitis (Hepatitis B, C), hemochromatosis, and non-alcoholic fatty liver disease (NAFLD)2. 
Chronic liver injury and its sequelae, hepatic fibrosis, cirrhosis, and hepatocellular carcinoma 
(HCC), are discussed below.  
 2 
1.1.1 Hepatic Fibrosis 
Hepatic fibrosis, a manifestation of chronic liver disease, is a wound healing response that results 
in excessive, dysregulated collagen deposition from activation of hepatic stellate cells (HSC). This 
could be a result of inflammation and the release of numerous paracrine and autocrine growth 
factors and inflammatory chemokines from injured hepatocytes, resident macrophages, infiltrating 
inflammatory cells, and HSC themselves. Hepatic fibrosis can result from a variety of injurious 
stimuli to the liver including chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, 
chronic alcohol exposure, non-alcoholic steatohepatitis, primary biliary cirrhosis, or autoimmune 
hepatitis 3. The convergence of each of these injurious stimuli on a similar fibrotic injury response 
has made the identification of therapeutic targets to prevent or reverse fibrosis a priority. 
Importantly, early fibrosis is potentially reversible if hepatic injury can be curbed or repair 
enhanced 4-6. However failure to curb hepatic injury in the setting of fibrosis may eventually lead 
to the development of cirrhosis, setting the stage for liver failure or (in a subset of patients) liver 
cancer. 
1.1.2 Cirrhosis 
In the setting of chronic liver injury, the persistence of hepatocyte cell death and fibrotic response 
can lead to cirrhosis which is characterized by the presence of regenerative nodules disrupting the 
normal architecture as well as causing altered blood flow and portal hypertension7. In addition to 
the degeneration/necrosis of hepatocytes and replacement of parenchyma with fibrotic liver tissue 
that is associated with hepatic fibrosis, cirrhosis characteristics include regenerative nodules, 
defenestration of sinusoidal endothelial cells, venous occlusion, and ultimately loss of liver 
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function. Unlike hepatic fibrosis which is clinically silent, loss of liver function in cirrhosis is 
associated with specific clinical signs including ascites formation, portal hypertension, and 
varices8, 9. In a subset of cirrhosis patients, hyperplastic nodules undergo increasing genomic 
stability as a result of unrelenting hepatocyte necrosis and proliferation, eventually forming 
dysplastic nodules that can lead to HCC10.  
1.1.3 Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer (83% of all cases) and 
is the 5th most common neoplasm worldwide 10. It is a disease of grim prognosis with a 5 year 
survival rate of only 8.9% in the U.S.A. 10 Currently, tumor resection and liver transplantation are 
the only curative treatments available11. While orthotopic liver transplantation is effective in the 
treatment of HCC, it is associated with high morbidity, cost, life-long immunosuppressive therapy 
and a shortage of donor organs. In the last decade, molecular therapies have been explored as a 
potential option for HCC treatment. Sorafenib, a multikinase inhibitor targeting Raf, VEGFRs, 
and PDGFRα/ß, is currently the only chemotherapeutic which has been shown to be effective in 
the treatment of HCC 12, 13.  
1.2 ANIMAL MODELS OF CHRONIC LIVER INJURY 
Animal models are crucial tools for the investigation of the pathogenesis of hepatic fibrosis during 
chronic liver injury. Much of what is known about hepatic fibrosis and the signal transduction 
pathways and cell interactions arising in the injured liver come from these models, which provide 
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important advantages over clinical research including i) defined timepoints of injury and controlled 
injury conditions, ii) shorter time frame for disease development, iii) relatively larger liver 
sampling compared to human liver biopsy, iv) ability to use invasive terminal procedures (ex: liver 
perfusion and HSC isolation) in a non-post mortem setting, and vi) the use of genetically modified 
animals. This last point will be discussed later in this dissertation in Section 4.1.  
Animal studies are also important complements to culture activated models of HSCs in 
vitro (discussed further below) due to the ability to study cells in intact organs with dynamic cell-
cell interactions, cell-matrix crosstalk, and exposure to immune, vascular, metabolic, endocrine 
and other physiologic/pathophysiologic stimuli.  
Despite the indispensable nature of animal models in the study of liver injury, the utility of 
these models is limited by the fact that rodents and humans often do not succumb to similar 
hepatotoxic agents. For example, mice are extremely averse to alcohol and rapid metabolism of 
alcohol in mice prevents high alcohol blood levels. Alternatively, Hepatitis C virus (HCV), which 
is a leading cause of infectious chronic liver injury in the developed world, does not infect rodent 
hepatocytes. Chronic liver injury in the setting of metabolic disease such as non-alcoholic fatty 
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are complex diseases that cannot 
be recapitulated with a single injury agent.  
The complexity of these diseases has led to the development of a variety of agents used to 
induce chronic liver injury including hepatotoxic chemicals (ex: CCl4, TAA), physical surgery (ex: 
BDL), Special feed diets (ex: high fat diets), immune reaction, and genetic modification (ex: 
MDR2 knockout).  The extreme diversity of injurious stimuli leading to hepatic fibrosis 
necessitates the use of complementary animal injury models to demonstrate the broad relevance 
of any findings at the molecular level. In light of this consideration, the animal studies shown in 
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the following chapters are performed on at least two models of animal injury, one hepatotoxic liver 
injury model (CCl4) and one model of cholestasis (BDL, DDC).  
1.2.1 Carbon Tetrachloride 
Chronic administration of carbon tetrachloride (CCl4) is a widely used and extensively 
characterized hepatotoxic model of liver injury in mice and rats due to its high degree of 
reproducibility, ease of administration, and predictable timecourse of injury and recovery 
encompassing early and late stages of fibrosis, cirrhosis, and eventually HCC. The mechanism of 
CCl4-induced liver injury is well studied. CCl4 is metabolized in pericentral hepatocytes by the 
cytochrome P450 family (CYP family) of enzymes to form the reactive radical compound 
trichloryl methyl (CCL3*). Reaction with this compound ultimately results in centrilobular 
necrosis through oxidative stress, mitochondrial dysfunction, membrane dysfunction, and reduced 
protein synthesis14. Resulting hepatotoxic damage and inflammation over repeated exposures (ex: 
injections) followed by short recovery periods in between injections emulates periods of injury 
and recovery which characterize human pathology. With biweekly injections, mice develop robust 
fibrosis after 4 weeks, and a pre-cirrhotic/cirrhosis phenotype at 8-12 weeks of injection. 
Continued administration leads to the development of HCC, making CCl4 a very versatile model.  
1.2.2 Bile Duct Ligation 
Bile duct ligation is the archetypal model of obstructive cholestatic liver injury. Ligation of the 
common bile duct leads to rapid ductular proliferation, portal inflammation, and portal fibrosis. 
Unlike hepatotoxic liver injury models targeting pericentral hepatocytes, cholangiocytes and 
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periportal hepatocytes bear the brunt of injury in BDL. This last point is particularly important 
because human hepatic fibrosis is more commonly distributed in the peri-portal rather than peri-
central regions15 – making cholestatic liver injury models a crucial tool for investigators to verify 
translational relevance.  
In contrast to other models of cholestasis, BDL has been extensively characterized based 
on the relative contributions of hepatic stellate cells and portal fibroblasts to the overall 
transdifferentiated myofibroblast population. Using the absence of Vitamin A in Col-GFP 
expressing cells to distinguish between HSCs and portal fibroblasts, Iwaisako et al showed that 
the majority of myofibroblasts arising early timepoints post-BDL (5 days) are derived from 
Vitamin A-negative portal fibroblasts rather than HSCs16. At increasing timepoints post-surgery, 
the proportion of myofibroblasts derived from HSCs increases until it eventually becomes the 
majority source of myofibroblasts.  In our studies described below (Chapters 2-4), we analyze 
livers 5 days and 2 weeks post-BDL. These two timepoints were chosen to reflect the differential 
contributions of portal fibroblasts and HSCs to the activated myofibroblast population at each of 
these times17.  
1.2.3 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) 
DDC-induced liver injury is a well-studied xenobiotic model of sclerosing cholangitis which is 
used widely for the study of chronic cholestatic liver disease18. DDC is easily administered as a 
modified diet and does not involve invasive surgery in contrast to BDL. Furthermore, while BDL 
models secondary biliary fibrosis/cirrhosis as a result of large bile duct obstruction, DDC models 
primary biliary fibrosis/cirrhosis resulting from the formation of porphoryin plugs leading to 
cholestasis in the smaller bile ducts and contributing to a phenotype of sclerosing cholangitis, 
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ductular proliferation, peri-ductular fibrosis, and portal-portal fibrosis. Similar to other models of 
primary biliary cirrhosis, DDC is characterized by a reactive biliary epithelial cell (BEC) 
phenotype in which pro-inflammatory and pro-fibrogenic cytokines are secreted by BECs. The 
resulting injury and inflammation contribute to the activation and proliferation of myofibroblasts 
and peri-ductal fibrosis, which eventually form the characteristic ‘onion skin-type’ sclerosis 
histology which is a key hallmark of sclerosing cholangitis in humans18. 
1.3 CELLULAR ROLES DURING HEPATIC FIBROSIS 
Hepatic fibrosis is a complex process that involves interactions between many cell types within 
the liver 4. While myofibroblasts are the primary mediators of fibrosis 19, other cells influence and 
modulate the activity of myofibroblasts and their HSC precursors through the release of damage 
associated molecular patterns (DAMPS), reactive oxygen species (ROS), growth factors, 
cytokines, and chemokines that can stimulate quiescent HSCs to undergo activation and 
subsequent transdifferentiation to a myofibroblast form. In the following sections, we outline some 
of the different cellular roles of resident and infiltrating cells in the liver during chronic liver injury.   
1.3.1 Hepatic Stellate Cells 
Hepatic stellate cells, formerly known as Ito cells, lipocytes, pericytes, or fat-storing cells, are 
vitamin-A storing fibroblasts residing between hepatocyte sinusoids and sinusoidal endothelial 
cells known as the Space of Disse. In the normal liver, HSCs are thought to consist of 5-8% of 
total liver cells20.  In their quiescent state, HSCs are thought to function as storage cells for 
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retinoids (vitamin-A and its metabolites) and also maintain balanced turnover of ECM and regulate 
sinusoidal blood flow through their close association with sinusoidal endothelial cells (described 
further below). However in the presence of inflammation and other injurious stimuli, HSCs 
undergo a process of activation representing a continuum of changes in gene expression, 
morphology, and functional characteristics. These changes span the start of activation from a 
quiescent state to fully transdifferentiated myofibroblast and subsequent reversion or apoptosis (in 
the case of injury resolution). This process has been generally categorized into three major stages: 
initiation, perpetuation, and resolution21.  
Initiation consists of early changes in gene expression that make HSCs more receptive to 
future stimuli, can be triggered by variety of factors including paracrine growth factors, changes 
in surrounding ECM, and ROS and DAMPs released by damaged cells. Both resident liver cells 
(ex: hepatocytes, cholangiocytes, endothelial cells, etc.) as well as infiltrating inflammatory cell 
populations (ex: platelets, macrophages, etc.) contribute to the paracrine signals that initiate the 
process of HSC activation. Specific cellular roles and factors are detailed in the sections below.  
Once initiation of HSCs from a quiescent state has occurred, HSCs begin to undergo a 
series of discrete functional changes and begin to generate their own growth factors, cytokines, 
and chemokines which propagate the process of activation both in an autocrine as well as in a 
paracrine manner towards other HSCs. Due to the self-perpetuating nature of this process, this 
stage of HSC activation has been termed ‘perpetuation’ and represents the bulk of fibrogenic 
changes that occur during HSC activation. Among these changes are increased proliferation, 
migration, contractility, fibrogenesis, and retinoid loss.  
Following regression of liver injury stimuli, myofibroblasts reduce in number through 
apoptosis or reversion to a quiescent phenotype. Lineage tracing experiments have demonstrated 
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that roughly half of myofibroblasts undergo apoptosis while the other half revert towards a semi-
quiescent HSC state following spontaneous recovery in a CCl4-induced injury model22. Gene 
expression analysis of reverted HSCs show that they retain an intermediate profile of fibrosis-
associated genes between completely quiescent and activated HSCs.  
1.3.2 Kupffer Cells 
Kupffer cells (KCs) are specialized self-renewing macrophages that reside in the lining of walls of 
liver sinusoids that form part of the reticuloendothelial system (RES). In contrast to monocyte-
derived macrophages, KCs reside exclusively intravascularly and do not migrate23. In the absence 
of liver injury, KCs act primarily as antigen presenting cells that are positioned to sample the portal 
circulation and induce tolerogenic immune responses24. KCs are activated in response to several 
stimuli associated with chronic liver injury such as viral infection, alcohol, iron deposition, and 
high fat diet. Once activated, KCs are sources of important growth factors, cytokines, and 
chemokines that activate HSCs and rapidly recruit macrophages from circulation. 
1.3.3 Sinusoidal Endothelial Cells 
Sinusoidal endothelial cells (SECs) make up the endothelial lining of the sinusoid and are 
characterized by fenestrae on their surface which facilitate the filter and exchange of fluids and 
solutes and particulates between the sinusoidal blood and hepatocytes. SECs have intimately tied 
signaling feedback loops with HSCs due to their close proximity. For example, maintaining SECs 
in a quiescent, ‘differentiated’ phenotype relies in part on VEGF secreted by hepatocytes and 
HSCs. Alternatively, SECs share complex paracrine communications with HSCs and can 
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dramatically influence the ability of HSCs to remain quiescent or become activated. For example, 
Kruppel-like factor 2 (KLF2) expression in SECs triggers vasodilator, antithrombotic and anti-
inflammatory genes that deactivates HSCs in co-culture25. During chronic liver injury, SECs lose 
their fenestrations in a process known as capillarization25. Structurally, HSCs are wrapped around 
SECs and increased contractility of HSCs that accompanies their activation along with decreased 
nitric oxide production from SECs during liver injury can lead to vasoconstriction and raise portal 
pressure.  
SECs also play central roles in intrahepatic angiogenesis, the creation of new blood vessels 
from existing ones, This often occurs in tandem with fibrogenesis and serves several pathologic 
functions that propagate further hepatic fibrosis including the alleviation of hypoxia from 
expanding myofibroblast populations, the facilitation of movement of infiltrating inflammatory 
cells, and (in the case of cirrhosis/HCC) oxygenation of expanding cords of hepatocytes26. 
Angiogenesis is particularly relevant to the pathogenesis of HCC, discussed further below (Section 
5.3.1). SECs are therefore a key consideration in any cell-based targeting approach to modulating 
liver injury.  
1.3.4 Hepatocytes 
As the primary parenchymal cells of the liver, hepatocytes play many roles in response to chronic 
liver injury and are the targets of many hepatotoxic agents and pathogenic processes. Chronic liver 
diseases promote compensatory hepatocyte regeneration and cell death (apoptosis/necrosis) that 
triggers the activation of quiescent HSCs through the release of ROS, DAMPs, cytokines & growth 
factors to influence myofibroblast activation 27, 28 and proliferation 29 30. Among the growth factors 
secreted by hepatocytes that play an important role in HSC activation are vascular endothelial 
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growth factor (VEGF), insulin-like growth factor 1 (IGF-1)31, and PDGF (see Figure 3 and Table 
I). In addition, hepatocytes are a major source of matrix metalloproteinases (MMP-2, MMP-3, and 
MMP-13) and tissue inhibitors of matrix metalloproteinase (TIMP-1 and TIMP-2) which are 
integral parts of the remodeling of fibrotic tissue during chronic liver injury32. 
Robust hepatocyte regeneration and clearance of necrotic hepatocyte cell debris and 
apoptotic bodies are thought to be important processes in recovery from liver injury – both for the 
restoration of liver metabolic function as well as mitigation of pro-inflammatory and pro-fibrotic 
signals that can exacerbate liver injury. However, the rapid turnover of hepatocytes as a result of 
chronic injury stimulus can eventually lead to genomic instability and dysplasia and (in some 
cases) can progress to cirrhosis or even HCC.  
1.3.5 Cholangiocytes 
Under physiologic conditions, cholangiocytes lining the bile ducts of the biliary tree of the liver 
actively contribute to the volume and composition of biliary secretions under various hormone-
regulated events. Initially following injury, cholangiocytes become activated and begin to 
proliferate in order to compensate for loss of biliary epithelial cells during injury and retain 
secretory functions. In response to injury, cholangiocytes undergo a neuroendocrine-like 
transdifferentiation in which cholangiocytes synthesize and react to a number of neuroendocrine 
factors including secretin, VEGF, follicle-stimulating hormone (FSH), histamine, estrogens, and 
others (see Maroni et al for review33). These factors not only sustain cholangiocyte proliferation 
but modulate immune response, the angiogenesis and structural changes associated with ductular 
reaction, and the progression of hepatic fibrosis.  
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1.3.6 Portal Fibroblasts 
Cholangiocyte injury during biliary fibrosis is also associated with the activation of portal 
fibroblasts. These cells are a heterogenous group of peri-portal fibroblasts that have been shown 
to contribute substantially to the myofibroblast population of biliary fibrosis – particularly in early 
stages of cholestatic liver injury. Lineage tracing studies in mice following BDL show that the 
contribution of portal fibroblasts to the overall myofibroblast (Col1a1-positive) population may be 
up to 73% at 5 days post-BDL and 49% at 17 days post-BDL16. The relative contribution of portal 
fibroblasts to the myofibroblast population decreases with progressive liver injury, with HSCs 
resuming the role of main precursor to myofibroblast differentiation at later BDL timepoints (20 
days post-surgery)16. Due to this phenomenon, portal fibroblasts have been described as “first 
responders” for the initiation of fibrosis following biliary injury34. The varying contribution of 
portal fibroblasts to the myofibroblast population in BDL underscores the need to evaluate biliary 
fibrosis separately from other forms of liver injury (ex: hepatotoxicity) when trying to identify 
potential therapeutic targets in chronic liver injury.  
1.3.7 Inflammatory Cells 
Liver injury is accompanied by infiltrating immune cells which have a variety of pro- and anti-
fibrogenic effects through their effects on HSCs, ECM, and other resident liver cells. For example, 
monocyte-derived macrophages can propagate fibrosis by promoting NF-κB mediated HSC 
survival through the release of IL-1 and TNF. In contrast, these macrophages can also assist in 
fibrosis resolution by the release of ECM degradation mediators MMP-12 and MMP-13, as well 
as the killing of HSCs through the release of TNF-related apoptosis-inducing ligand (TRAIL)35. 
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Natural killer (NK) cells are also involved in HSC killing through FasL and TRAIL. B 
Lymphocytes also play an anti-fibrotic role through an Ig-independent mechanism that reduces 
ECM production but does not reduce the number of myofibroblasts36.  
In addition to exerting effects on HSCs and fibrogenesis, inflammatory cells are central to 
the removal of cell debris from necrosis. In particular infiltrating hepatic macrophages are 
important phagocytic cells that aid in the resolution of fibrosis by removing cell debris from dying 
hepatocytes, HSCs, and other inflammatory cells that can otherwise stimulate fibrotic activity37.  
1.4 PDGF SIGNAL TRANSDUCTION 
PDGFs are cysteine-knot-type growth factors that have been identified as four different disulfide-
bonded polypeptide chains (A, B, C, D) which form five known dimer configurations: AA, AB, 
BB, CC, DD (see Fig. 1) 38-41. Each of these ligand dimers binds differentially to PDGFRs: type 
III receptor tyrosine kinases (RTK) that possess five extracellular IgG domains and an intracellular 
kinase domain separated by a transmembrane helix 42. PDGFRs exist as α or ß monomers in the 
plasma membrane that are bound by dimeric PDGF ligands simultaneously to form αα, αß, and 
ßß receptor dimers, and upon binding trigger reciprocal tyrosine phosphorylation of specific 
residues of each receptor 43, 44.  Phosphorylation of tyrosine residues in the kinase domain increases 
catalytic efficiency and serves as binding sites for signaling molecules including other kinases as 









Figure 1: PDGF Signaling Pathway. Differential binding of PDGF ligands to PDGFRs highlighting key tyrosine 
phosphorylation residues of the intracellular kinase domain of PDGFRα homodimer and their downstream effectors 
(boxed insert). Red arrows: known in vivo ligand binding.  Black arrows: documented in vitro ligand binding only. 
Red bracket: autoinhibitory activity (SHP2). Not included are Tyr 754, and Tyr849, which are also signaling 
tyrosine residues.  
 
PDGFRα and PDGFRß have distinct but overlapping sets of ligands and downstream 
effectors. While the differences between PDGFRα and PDGFRß function in various cell types are 
likely primarily due to their spatiotemporal pattern of expression, there are some discrete 
differences between α and ß forms as Crk binding is specific to PDGFRα and PDGFRαß 
heterodimers confer increased mitogenicity compared to α and ß homodimers due to sustained 
activation of Ras and Erk2 45. However the physiologic roles of PDGFRαß dimers are not yet 
clear. Downstream effectors of PDGFRα signaling include enzymes such as PI3K, MAPK, PLCγ, 
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Src, and Shp-2, as well as non-enzymatic adaptor molecules such as Crk, Shc, and Grbs. These 
downstream mediators are important for a variety of cell processes including proliferation, cell 
survival, cell growth, and differentiation (see Fig. 1). Specific downstream mediators and tyrosine 
residue phosphorylation sites involved in PDGFR signaling have been previously reviewed 39, 44. 
1.5 PDGFRα IN LIVER DEVELOPMENT 
Studies of both PDGFRα and PDGFRß have demonstrated that they are essential in embryonic 
development. Mice lacking either PDGFRα or PDGFRß are embryonic lethal 46, 47, with PDGFRα 
homozygous null mutant embryos showing incomplete cephalic closure and apoptosis of migrating 
neural crest cells as well as skeletal and vascular abnormalities. In the context of embryonic livers, 
PDGFRα is present in important mesenchymal and mesothelial subpopulations that modify the 
microenvironment to support developmental processes. For example, PDGFRα may mark an 
important population of mesenchymal progenitor cells that promote hepatoblast differentiation 
through direct contact and growth factor secretion. These cells, isolated by expression of Dlk-1 
and PDGFRα from embryonic day 13.5 (E13.5) murine livers, show direct and indirect effects on 
hepatoblast maturation through direct contact and transwell co-culture experiments, respectively 
48. This study is consistent with previous evidence of mesenchymal stem cell isolation using 
PDGFRα 49 as well as mesenchymal-supported hepatoblast maturation 50. Thus, PDGFRα may 
mark a small, but active subpopulation of mesenchymal stem/progenitor cells that indirectly 
influence the development of hepatoblasts in fetal liver development. 
Consistent with a supportive role of PDGFRα+ cells in hepatoblast development, 
PDGFRα+ stromal cells in murine fetal liver were also found to be necessary for erythropoiesis 
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51.  In this study, it was shown that the PDGFRα+ fraction of murine fetal liver is necessary for the 
expansion of erythrocyte progenitor colonies in vitro, while maternal injection of anti-PDGFRα 
monoclonal antibody led to inhibition of erythropoiesis. In addition, exogenous PDGF-AA and 
PDGF-BB stimulated erythropoietin (EPO) production in fetal liver cells. These studies 
demonstrate an important role of PDGFRα signaling in EPO production and hematopoiesis in the 
liver, though a specific relationship between PDGFRα signaling and EPO production was not 
elucidated in this study. 
While traditionally considered a receptor of mesenchymal cells, we observe both 
cytoplasmic and perinuclear expression of PDGFRα in a subset of epithelial cells during mouse 
embryonic liver development with peak expression from E10 to E12 52, 53. In contrast to the 
mesenchymal cell profiles from isolated PDGFRα+ cells reported by others 48, we show that a 
subset of HNF4α+ hepatoblasts from embryonic liver tissue express PDGFRα and that inhibition 
of PDGFRα signaling in embryonic liver cultures results in decreased  survival and proliferation 
of these cells. This could be a cumulative effect of PDGFRα suppression in various 
aforementioned cell types. Following this mid-gestational period, PDGFRα expression 
dramatically decreases throughout murine fetal liver development and remains low in adult murine 
liver.  
In combination with previous findings that PDGFRα marks a population expressing 
mesenchymal markers, the finding of PDGFRα in a subset of hepatoblasts brings to light the 
possibility that this receptor may be expressed in epithelia developing from a mesenchymal 
subpopulation - a process known as mesenchymal-to-epithelial transition (MET). Such an 
occurrence has been previously been reported in mouse hepatic stem cells in vivo, which co-
express markers of both epithelial (CK8/18) and mesenchymal (vimentin) markers at similar 
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embryonic timepoints 54. In fact the mesenchymal population characterized in this study was 
isolated based on intermediate expression of Dlk-1, a known marker of hepatoblasts and (at low 
expression) also a marker of mesothelial precursors 55. The contribution of mesenchyme to a subset 
of hepatoblasts and eventually to hepatocytes was also supported more recently by the fact that 
vascular endothelial growth factor receptor 2 (VEGFR2) – a known mesodermal marker – was 
also expressed in hepatic progenitors capable of contributing to a substantial portion of adult 
parenchyma shown by lineage tracing studies 56.  
PDGFRα expression was also identified in mesothelial and submesothelial cells of E12.5 
murine livers, which were proposed to be precursors of hepatic stellate cells 57. As with the above-
mentioned studies, PDGFRα was used primarily as an identifying marker and a specific role of 
PDGFRα signaling was not elucidated. In the case of PDGFRα expression in mesothelial and 
submesothelial cells of the liver, it can be speculated that PDGFRα plays a pro-proliferative 
response which may be important for expansion of this HSC precursor population during 
development.   
The presence of PDGFRα in mesenchymal, mesothelial, and epithelial cells of the 
developing liver may provide insight on its importance in adult liver pathophysiology. For 
example, the expression of PDGFRα in mesothelial precursors of HSC including ‘sub-mesothelial 
cells’ and their transitional cell counterparts 57, as well as it’s potential expression in a subset of 
hepatoblasts, may signify that PDGFRα is serving as part of a modulatory proliferative 
transcription program which is upregulated in liver development and pathology while being 
suppressed in quiescent, non-proliferative states. Further investigation of the effects of PDGFRα 
inhibition in an in vivo or ex vivo developmental context will help to shed light on the function of 
this receptor in supporting hepatoblast maturation, erthyropoiesis, or mesothelial/submesothelial 
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migration and HSC formation. Eventually since tumorigenesis often represents reawakening of the 
developmental programs that may contextually encompass epithelial-to-mesenchymal transition, 
PDGFRα modulation may provide novel therapeutic opportunities in HCC. 
1.6 PDGFRα IN LIVER REGENERATION 
Our lab has previously investigated the role of PDGFRα in liver regeneration using the well-
known 2/3 partial hepatectomy (PH) model in which 2/3 of the liver mass is surgically removed 
and compensatory regeneration is subsequently studied at discrete, well characterized timepoints 
58. In control mice, PDGFRα activation was evident at 3 hours although its total levels were 
unequivocally elevated at 24 hours. For further studies, we first generated mice lacking PDGFRα 
in hepatocytes (Albumin-cre excision of floxed Pdgfra). These mice were indistinguishable from 
their littermates. When subjected to PH, an initial delay in Akt signaling by 3 hours post-PH was 
soon offset by upregulation of EGFR and hepatocyte growth factor receptor Met. Both epidermal 
growth factor receptor (EGFR) and Met have been shown to be crucial mediators of normal liver 
regeneration 59. In combination with previous findings of Pdgfra and Pdgfa upregulation in rats 
during shRNA-mediated inhibition of EGFR following 24 hour PH, our results suggests a potential 
reciprocal regulation between PDGFRα and EGFR 60. These studies exemplify the well-known 
phenomenon of growth factor signaling compensation in liver regeneration 58. Rather than 
diminish the importance of the PDGFRα signaling axis in hepatocyte regeneration in this model, 
these results attest to the signaling ‘flexibility’ that is a well-recognized theme in PH. Similar to 
most growth factors in liver regeneration following PH, ligands of PDGFRα appear to play a 
significant, but replaceable role.  
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PDGF ligands including ligands for PDGFRα, are generally known for their mitogenic 
effects in mesenchymal-derived stromal cells of the liver. There is however important evidence 
that hepatocytes themselves may respond to PDGFs. A recent study that examines the effect of 
growth factors on murine hepatocytes reveals a modest but significant and direct mitogenic effect 
of PDGF-AB on primary murine hepatocytes 61. The importance of this finding is underscored by 
the fact that prior to this study, only HGF and ligands of EGFR were identified as direct mitogens 
on primary hepatocytes in chemically defined medium 58. Evidence of PDGF-induced mitogenesis 
of hepatocytes in vitro or in vivo in the context of liver regeneration is sparse at this time. However, 
due to the increasing emergence of PDGFRα signaling as a therapeutic target in pathologic liver 
states (see below), the elucidation of regenerative hepatocyte PDGFRα signaling may be important 
to fully interpret the effects of therapeutic PDGFRα inhibition. Together, these studies suggest that 
PDGFRα signaling may occur in the hepatic parenchyma during liver regeneration – possibly 
contributing to mitogenesis. This is in contrast to models of chronic liver injury (discussed below) 
where PDGFRα seems to be located primarily in the NPCs.  
1.7 PDGFRα IN LIVER FIBROSIS 
Findings in the literature regarding PDGFRα signaling in chronic liver injury strongly support a 
pro-fibrotic role of this receptor. However, cell-specific studies of PDGFRα designed to delineate 
the function of this receptor in individual cell populations in the liver are currently lacking. 
Different resident cell populations play potentially antagonistic pro- or anti-fibrotic roles in the 
setting of chronic liver injury62 and it is therefore conceivable the biologic endpoints of PDGFRα 
signaling (ie survival, proliferation) may contribute to injury progression in specific cells (ex: 
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activated HSC) while ameliorating injury in others (ex: hepatocytes). In addition our knowledge 
of downstream targets of PDGFRα signaling in liver pathogenesis is limited and elucidation of 
these will be important for the identification of potential therapeutic targets. 
The role of PDGFRα signaling in the setting of fibrosis is currently unclear, as many studies 
present compelling data leading to differing conclusions on its contributions and relative 
importance compared to its related isoform PDGFRß in HSC activation and proliferation. In the 
following sections, we discuss some of the evidence for the localization and function of PDGFRα 
in the fibrotic liver, highlighting conflicting results and interpretations in the literature.  
1.7.1 Relative Contributions of PDGFRα vs. PDGFRß in HSC Activation: Reconciling the 
Evidence 
Though PDGFRß has long been established as a functional marker of activated HSCs 63, PDGFRα 
has only recently emerged as a potential mediator of HSC activation in hepatic fibrosis. Early 
studies of PDGFR isoforms in HSC emphasized the importance of PDGFRß due to the 
upregulation of this isoform at mRNA and protein level in contrast to the constant levels of 
PDGFRα reported following carbon tetrachloride (CCl4) or bile duct ligation (BDL)-mediated 
injury in rats 64. Over the next couple of decades, PDGFRα expression in HSCs of fibrotic livers 
became increasingly evident. PDGFRα mRNA is highly expressed in α-smooth muscle actin 
(αSMA) positive NPCs of cirrhotic human livers localized in the perisinusoidal region 65. This 
study also showed that PDGFRα is upregulated in stromal and sinusoidal cells in human livers 
during cirrhosis and reported a strong correlation between expression of PDGFRα and PDGFRß 
in human livers to the histology activity index (HAI, Knodell’s score) and type III collagen 
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deposition 65. These findings were subsequently affirmed when PDGFRα upregulation was also 
observed in whole cell lysates of rat livers treated with CCl4 66, and has most recently been 
confirmed in the murine BDL 67 and CCl4 models 68. The exception of this trend is a study in BDL 
rats, indicating a potential difference in PDGFRα signaling role in toxic and cholestatic fibrosis 
models (discussed further below) 69. 
Findings from studies of PDGF signaling in isolated rat HSC and culture activated 
myofibroblasts indicate that PDGFRαα homodimer is not likely to be the primary PDGFR isoform 
involved in HSC activation/proliferation as evidenced by studies showing that culture-activated 
HSCs showed selective proliferative response to PDGF-B and PDGF-D isoforms and lacked 
mitogenic response to PDGF-AA (specific for αα homodimer, see Fig. 1) 69. There is however 
some discrepancy between findings in this model system as an earlier study showed a small but 
significant (2-3 fold) proliferative effect of PDGF-AA 70. Of particular importance is a study that 
noted a comparable level of PDGF-AA-induced mitogenicity in HSC lines isolated from patients 
71. This study also showed that PDGF-AA may help activated HSCs overcome proliferative 
inhibition from ECM molecules such as collagen I. It is worth mentioning that part of the 
discrepancy between the mitogenic responses of HSCs to PDGF-AA between studies may be 
related to the specific concentration of ligand used. The studies showing mitogenicity of PDGF-
AA in rat 70 and human derived HSCs 71 both showed maximal proliferative stimulation of HSCs 
at 10ng/mL PDGF-AA. In contrast, the study of rat culture-activated HSC, which showed no effect 
of PDGF-AA only utilized a single and higher concentration (50ng/ml).  
Despite the relatively minor role of PDGFRα in proliferation of culture activated HSCs, 
Hayes et al recently showed that PDGFRα is upregulated in HSCs following CCl4-mediated 
fibrosis in mice and that activation of PDGFRα may contribute to hepatic fibrosis since fibrosis 
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was reduced following CCl4-mediated injury in mice heterozygous for PDGFRα 68. While previous 
studies have reported PDGFRα expression in HSC from animals 64, 66 and patients 65, the study 
from Hayes et al is the first report indicating that genetic reduction of PDGFRα signaling in vivo 
reduces hepatic fibrosis in chronic liver injury, thus paving the way forward for possible 
therapeutic inhibition.  
What are possible explanations for the seeming discrepancies of the profibrotic 
contribution of PDGFRα signaling between culture-activated HSC and murine HSCs heterozygous 
for PDGFRα? The answer is unclear at the moment, but may involve one or more factors, including 
(i) an effect on PDGFRαß heterodimer expression, (ii) a lesser role of PDGFRαα signaling in HSC 
activation/proliferation, and (iii) differences in receptor isoform signaling function. With regards 
to (i), PDGFRαß heterodimer is not known to interact with PDGF-AA (Fig. 1) but still requires 
PDGFRα expression. If PDGFRαß is playing an active role in HSC activation, PDGFRα might 
only contribute to HSC proliferation and myofibroblast activation through its ability to complex 
with the ß receptor. This explanation is consistent with the findings of close PDGFRα and 
PDGFRß co-localization in fibrotic livers 65, 68, as well as the presence of PDGFRα 
phosphorylation in chronic liver injury (67, unpublished observations). 
While PDGFRαß heterodimer function is a plausible explanation for these studies, 
PDGFRα is still likely to contribute to HSC activation through (ii) its homodimer form as PDGF-
AA (a ligand specific to PDGFRαα homodimer) did show a significant, albeit lesser, effect on 
proliferation/intracellular calcium in culture-activated HSCs. Furthermore, transgenic mice 
overexpressing PDGF-A in hepatocytes spontaneously develop fibrosis 72. This study lends strong 
support to the notion that PDGF-AA/PDGFRαα signaling alone is at least sufficient to initiate 
hepatic fibrosis in mice – though whether hepatic fibrosis is propagated by active PDGFRαα 
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signaling, or is reliant on the subsequent autocrine or paracrine release of other factors (such as 
other PDGF isoforms) is not assessed in this study.  
Finally, future investigations should consider that (iii) downstream signaling functions of 
PDGFRs in HSCs may be isoform specific. Studies of chemically-defined mouse embryonic 
fibroblasts have shown that PDGFRαα, αß, and ßß activate distinct downstream signaling 
pathways 73. Primary cell culture studies to determine differences of PDGFRα and PDGFRß 
signaling in genetically PDGFR-defined HSCs or myofibroblasts may ultimately be necessary to 
fully understanding the specific roles of PDGF/PDGFR in HSC activation, survival, or 
proliferation. 
The development of several transgenic murine models overexpressing specific forms of 
PDGF in hepatocytes under albumin promoter-controlled transgene expression support a potential 
role of PDGFRα in the development of fibrotic changes in the liver. In addition to transgenic 
overexpression of PDGF-A (described above), PDGF-B overexpression in hepatocytes leads to 
development of spontaneous fibrosis in mice 72, 74. Similarly, the overexpression of PDGF-C, a 
known ligand of both PDGFRα and PDGFRß, in transgenic mice leads to the spontaneous 
development of liver fibrosis, steatosis, and HCC 75. Both PDGFRß and PDGFRα were 
upregulated in whole liver lysates in this model. In addition, PDGF-C overexpression in 
hepatocytes causes expansion of NPC populations including sinusoidal endothelial cells and 
activated HSCs 76, supporting potential PDGFRα expression in both of these populations. It should 
be noted however that neutralization of PDGF-C in other murine strains by genetic knockout or 
neutralizing antiserum does not confer protection to BDL-induced liver injury 67. Data from this 
study indicates that PDGF-C may primarily mediate its fibrotic effects through PDGFRß rather 
than PDGFRα, as PDGFRß mRNA and total/phosphorylated protein level - not PDGFRα - is 
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exclusively upregulated in response to PDGF-C neutralization. These authors confirm that this is 
not due to differential expression of other PDGF isoforms. Thus, at least in the context of murine 
experimental biliary fibrosis it appears that PDGFRß, not PDGFRα, is the primary activated 
receptor in response to PDGF-C in a pathophysiological (non-overexpressed) setting. Nevertheless 
PDGFRα is still substantially upregulated and phosphorylated in these settings, indicating 
activation of this receptor in biliary fibrosis.  
Evidence suggesting the presence of PDGFRα in HSC and activated myofibroblasts sheds 
new light on much of the current literature regarding PDGFR signaling in HSCs and activated 
myofibroblasts in hepatic fibrosis/cirrhosis – the majority of which focus exclusively on 
assessment of PDGF-BB/PDGFRß signaling. In light of the fact that PDGF-BB activates both 
PDGFRα and PDGFRß, much of this data can be reinterpreted to consider a potential contribution 
of PDGFRα isoform.  
1.7.2 TGF-ß/PDGFRα Crosstalk in HSCs 
Thus far, we have primarily considered only ligand-dependent mechanisms of PDGFR activation 
in hepatic fibrosis. However, a recent study sheds new light on a potential ligand-independent role 
of PDGFRα in HSCs. Liu et al show compelling evidence that PDGFRα appears to be necessary 
for SMAD2 signaling downstream of TGF-ß receptor in human HSCs in vitro 77. This was 
demonstrated through the shRNA knockdown of PDGFRα in human HSC and HSC cell line LX-
2, which led to a decreased RNA expression of TGF-ß receptor I (TßRI) and SMAD2 
phosphorylation activity of TGF-ß receptor II (TßRII). SMAD-2 is a key mediator of fibrosis in 
myofibroblasts in the setting of acute and chronic liver injury 78, indicating a potential role of 
PDGFRα in this important arm of TGF-ß signaling. This study brings to light a novel mechanism 
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of indirect PDGFRα activation triggered by interaction of PDGFRα with TßRII (summarized in 
Fig. 2). The modulation of PDGFRα expression in response to TGF-ß is consistent with previous 
findings in other fibroblast populations including scleroderma skin fibroblasts 79. Though PDGFRα 
activation in the absence of direct ligand binding has been previously reported 80, this is the first 
report indicating that PDGFRα is necessary for a major fibrotic signaling pathway in the liver. 
Combined with previous studies showing TGF-ß-induced PDGFRα in a Ras-mutant murine 
hepatocyte model of EMT81, there may be a reciprocal regulation between TGF-ß and PDGF 
signaling.  
Experimental RTK inhibitors often function by preventing the activating interaction of 
ligands and their receptors, either by binding ligands or receptors themselves to prevent 
phosphorylation. The findings by Liu et al suggest that PDGFRα may function in chronic liver 
injury not only through RTK autophosphorylation following ligand binding, but also through a 
ligand independent mechanism involving monomeric PDGFRα. Further investigation of the extent 
of the latter form of PDGFRα signaling in vivo will be particularly relevant to predict the 
effectiveness of targeted PDGFRα inhibitors, which may only prevent ligand binding. Ligand-
independent PDGFRα activation has been shown previously in the setting of proliferative vitreal 
retinopathy in which mitochondrial ROS triggers the activation of Src family kinases (SFK) 
leading to phosphorylation of monomeric PDGFRα 82. In another example, the PDGFRα-specific 
inhibitor Olaratumab (discussed further below) failed to inhibit bone marrow-induced Akt 
activation in metastatic prostate cells in vitro and in vivo as a result of ligand-independent 
transactivation of PDGFRα 83, 84. Despite these examples, exclusive monomeric activation of 
PDGFRα during liver injury is unlikely due to the overwhelming evidence that PDGF ligands play 
a central role in the initiation and progression of fibrosis 53, 72, 74, 75, 85. Thus it is likely that ligand-
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independent PDGFRα activation through TGF-ß signaling arm is only one mode of activation of 
downstream PDGFRα signaling. 
 
Figure 2: TGF-ßR/PDGFRα Signaling Crosstalk in HSC. Ligand dependent and independent signaling pathways 
are shown. During ligand-independent signaling, PDGFRα is recruited to TßRI/TßRII complexes by TGF-ß 
stimulation. Through interaction with TßRII, PDGFRα promotes internalization and trafficking of TGF-ß receptors 
into   the   early   endosomes,  where   phosphorylation   of   SMADs   occurs   and TGF-ß signaling is activated. 
Knockdown of PDGFR- blocks endocytosis of TGF-ß receptors, thereby inhibiting phosphorylation of SMADs. 
Activation of SMAD2/3 has been shown to lead to the upregulation of PDGF-A mRNA, which may indicate an 
autocrine mechanism of PDGFRα activation in HSC71, 86. Abbreviations: TGF-ß receptor II (TßRII). Adapted from 77.  
 
While the full nature of PDGFRα signaling in this model is not elucidated in this study, 
previous studies suggesting PDGF-induced activation of SMADs may offer insight. Treatment of 
rat primary HSC in culture with TGF-ß results in a selective increase of PDGF-A mRNA 
expression 87, which may implicate an autocrine activation of PDGFRα in HSC (see Fig. 2). It has 
previously been shown that co-treatment of cultured HSC with TGF-ß and PDGF (unspecified 
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isoform) leads to c-Jun N-terminal kinase (JNK) mediated activation of SMAD2/3 88. In vitro, high 
TGF-ß1 concentrations in a study of aortic smooth muscle cells and fibroblasts were shown to 
cause differential modulation of PDGF-AA (increased) and PDGFRα (decreased) 86 responsible 
for an inhibition of PDGF-AA mediated growth. In light of the study by Liu et al, it is interesting 
to speculate that in addition to transcriptional regulation of PDGF-A and PDGFRα by TGF-ß, 
posttranscriptional regulation may also be occurring via direct binding and internalization of 
PDGFRα by ligand-activated TßRs in aortic smooth muscle cells and fibroblasts of the 
aforementioned study.  
1.7.3 PDGFRα in Portal Myofibroblast Activation During Cholestatic Liver Injury 
PDGFRα expression in cholestatic liver injury was initially reported in myofibroblasts isolated 
from mice subjected to BDL at various timepoints 64. However, in contrast to PDGFRß, PDGFRα 
mRNA was not upregulated following BDL. Similarly, a more recent study of PDGFR and PDGF 
expression following BDL in rats shows that PDGFRα protein expression remains relatively 
unchanged, or only slightly elevated 69, in contrast to increased PDGFRß expression.  
Portal fibroblasts (PFs) are thought to play an important role in the initiation of fibrosis 
following cholestasis, particularly in early response to biliary injury (see section 1.3.6) 17. The 
question of whether PFs possess PDGFRs and are responsive to PDGF signaling is unclear at this 
time due to contradictory reports. PDGF-BB-mediated expansion of isolated peribiliary fibroblasts 
from rats that have undergone BDL express functional PDGFRß that contributes to 
myofibroblastic differentiation as measured by α-SMA expression 89. In addition, peribiliary 
myofibroblast conversion as measured by α-SMA was reduced upon treatment with PDGFR 
inhibitor STI571 (Gleevec). On the other hand, primary rat PFs isolated by Wells et al show no 
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mitogenic activity in response to PDGF-BB stimulation in vitro 90. Li et al demonstrate an 
interesting dichotomous effect of PDGF-BB on isolated rat PFs: exposure to PDGF-BB inhibited 
differentiation of PFs as measured by α-SMA but promoted proliferation 91 on collagen I-coated 
polyacrylamide gel supports. Finally, a study of murine BDL-derived activated PFs demonstrated 
that these fibroblasts were unresponsive to PDGF in contrast to HSCs 17. 
Thus, the range of PDGFs and their receptors expressed in PFs during biliary fibrosis 
requires further investigation in order to elucidate the potential autocrine or paracrine mechanisms 
of PDGF signaling in this population. While PDGFRα and PDGFRß have been previously reported 
in isolated HSCs during cholestatic liver injury 64, the absence or presence of PDGFRα in PFs 
prior to myofibroblastic changes remains unknown, as (to our knowledge) only PDGFRß has been 
confirmed in isolated PFs 89. This will be an interesting question to address in future studies, since 
PFs actively contribute to the myofibroblast population in early cholestatic injury 17 and biliary 
fibrosis and can be attenuated by targeted inhibition of PDGF signaling 92.  
1.7.4 PDGFRα Cellular Localization: Expression Patterns in Chronic Liver Injury 
As an autocrine and paracrine signaling factor, insight on the actions of PDGFRα signaling may 
be elucidated by their cellular localization in normal and pathogenic liver states. Localization of 
PDGFRα is most clearly demonstrated in NPCs of the liver including HSC and EC. Early reports 
of PDGFRα localization in normal and cirrhotic human livers identify PDGFRα expression in 
stromal cells of portal tracts as well as some sinusoidal EC and EC of the centrilobular veins 64, 65. 
Another group reported that mice with thioacetamide (TAA)-induced liver injury showed 
upregulated PDGFRα localizing in a sinusoidal pattern and in NPC 85. Consistent with a sinusoidal 
pattern of expression in cirrhosis, PDGFRα is overexpressed in EC of HCC associated with high 
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metastatic potential 93 and increased recurrence in patients. This is in line with evidence that tumor 
fibroblasts may become resistant to anti-VEGF therapy through the expression of PDGF-C 94. 
While one recent study denied the expression of PDGFRα in EC during CCl4-mediated liver injury 
in mice 68, it should be noted that this conclusion was based on lack of co-localization with CD31 
(PECAM), whose expression is low in liver sinusoidal EC (LSEC) following CCl4 treatment and 
thus may not be a sensitive marker in this model95. 
Currently the cellular localization of PDGFRα in hepatocytes during chronic liver injury 
is unclear. In situ immunostaining of human normal and cirrhotic liver shows no PDGFRα 
expression in hepatocytes 65. A recent study also reported an absence of hepatocyte PDGFRα in a 
murine CCl4 model 68. In contrast, PDGFRα is reportedly upregulated in regenerating rat 
hepatocytes following CCl4-mediated fibrosis 66 and contrary to the reported findings of other labs, 
we have found low level expression of PDGFRα in hepatocytes of human and murine liver 53. 
Further support for the presence of PDGFRα in hepatocytes stems from the finding that isolated 
murine hepatocytes proliferate in response to PDGF-AB in a chemically defined serum free growth 
media, and PDGF-AA or PDGF-BB exposure increases bromodeoxyuridine staining in these 
hepatocyte cultures 61. In contrast, another group has reported that primary hepatocytes in culture 
do not respond to PDGF-CC75. It should be noted that hepatocytes are heterogenous and different 
subpopulations (for example periportal versus pericentral) may express different receptors due to 
their differing metabolic roles or depending on the zonality of liver injury. Therefore, some 
subpopulations of hepatocytes may specifically upregulate PDGFRα/PDGFA signaling over 
others, as was evidenced in rat livers subjected to CCl4 in which pericentral hepatocytes selectively 
expressed PDGF-A 66. 
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 It remains undetermined whether a potential upregulation of PDGFRα in hepatocytes 
would be a reparative or pathologic response in chronic liver injury. Considering that hepatocyte 
survival and proliferation play crucial roles in liver regeneration and fibrosis, and detrimental roles 
in injury sequelae such as liver cancer, these findings warrant further investigation of PDGFRα 
signaling in hepatocytes. Elucidating the contribution of hepatocyte PDGFRα activation in disease 
pathogenesis, the signaling arms activated and their downstream cellular events will not only 
improve understanding of the pathobiology of this disease process but will also be relevant in 
validating PDGFRα as a therapeutic target. For these studies, hepatocyte-specific conditional 
knockouts of PDGFRα may lend themselves well 52.  
1.7.5 PDGF Sources in Injured Liver 
During liver injury, PDGFs are secreted by both resident and infiltrating cells of the liver including 
hepatocytes, Kupffer cells, cholangiocytes, infiltrating macrophages, and HSC themselves 
(summarized in Fig. 3, Table I). PDGFs from all of these sources likely converge on HSCs to 
trigger their activation and myofibroblast conversion, as well as proliferation and migration. 
PDGFs are also likely to exert autocrine effects on cell populations that express PDGFRs in 
addition to PDGF ligands, such as hepatocytes and activated HSCs. Kupffer cells and infiltrating 
macrophages are considered one of the primary sources of PDGFs involved in activating HSC. 
PDGF-B is expressed by infiltrating macrophages and Kupffer cells in patients with chronic 
hepatitis/cirrhosis, the expression of which correlates with inflammation and severity of fibrosis 
96. Hepatocytes influence HSC activation via activation of Kupffer cells as well as directly through 
the secretion of PDGFs and other signals during liver injury. Freshly isolated rat hepatocytes have 
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been reported to express mRNA for PDGF-A and PDGF-C, while PDGF-B mRNA was present in 
low amounts and PDGF-D mRNA was absent 87.  
Perhaps one of the most important sources of PDGFs in fibrosis is from HSCs themselves. 
Freshly isolated rat HSCs express PDGF-A, B, and low levels of D, while transdifferentiated 
myofibroblasts (HSC plated for 8 days) also express PDGF-C 87. Platelets are also known to be 
important secretory sources of many molecules and growth factors involved in liver regeneration 
including PDGFs 97. Supporting this, freeze-dried platelets storing growth factors including PDGF 
are able to promote hepatocyte proliferation in mice 98. 
Figure 3: PDGF Sources and Cell Interactions in Injured Liver. Shown are known or predicted sources of PDGF 
secretion during liver injury, and potential interactions between resident and infiltrating liver cell populations, during 
toxic or cholestatic liver injuries. Curved arrows represent potential autocrine stimulation. Green arrows represents 
events specific for cholestatic liver injury. Abbreviations: damage associated molecular patterns (DAMPs), hepatic 
stellate cell (HSC), platelet-derived growth factor (PDGF), reactive oxygen species (ROS), transforming growth factor 
beta (TGF-ß). Asterisk (*) represents discrepancy between studies. 
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The sources of PDGFs are most likely determined by the origin of the liver injury. In 
contrast to the lack of cholangiocyte PDGF positivity in tissue specimens from cirrhotic patients 
65, cholangiocytes from patients with biliary atresia do demonstrate strong expression of PDGF-
AA and PDGF-BB 99. 
1.8 THERAPEUTIC INHIBITION OF PDGF SIGNALING IN LIVER DISEASE 
Therapeutic inhibition of PDGF signaling focuses on three major approaches: the regulation of 
PDGF ligands, the inhibition of functional PDGF-PDGFR interactions using tyrosine kinase 
inhibitors (TKIs), and the inhibition of downstream intracellular signaling kinases. In this section, 
we focus on the first two approaches which specifically affect PDGF signaling.  
1.8.1 PDGF Ligand Neutralization 
Attempts to regulate the activity of PDGF ligands have focused on PDGF-B monomer and PDGF-
BB dimers due to the prominent role of this isoform as the most mitogenic PDGF ligand towards 
HSCs21, 70. One example of direct targeting of PDGF ligand is the development of MOR8457, a 
selective PDGF-BB monoclonal neutralizing antibody. Preclinical studies of MOR8457 in mice 
with biliary fibrosis showed a reduction in hepatic fibrosis and fibrosis-associated gene expression 
that was comparable or greater than that of similar doses of the non-selective multi-TKI 
Imatinib100. However, it is worth pointing out that these compounds were administered using 
different methods (weekly i.p. injections for the former, daily oral gavage for the latter). Similar 
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reductions in fibrosis was achieved using the neutralizing anti-PDGF-B monoclonal antibody 
AbyD3263 in mice injured via BDL or concanavalin A (ConA)101.  
1.8.2 PDGFR Inhibitors 
The development of tyrosine kinase inhibitors has been an important avenue for the research of 
new treatments for fibrosis and advanced liver disease. Many of the most successful inhibitors to 
date have co-targeted the components of the platelet-derived growth factor (PDGF) family of 
ligands and their receptors. While the ß isoform of this receptor: platelet-derived growth factor 
receptor beta (PDGFRß) has been at the forefront of PDGF signaling in the liver due to its 
important roles in myofibroblast activation during fibrosis 63, 64, several new studies have shown 
an emerging role of platelet-derived growth factor receptor alpha (PDGFRα) in liver 
pathophysiology that may identify this receptor as an important therapeutic target.  
Receptor tyrosine kinases are critical pharmacologic targets. Evidence from the 
development of both small molecule TKIs as well as monoclonal antibody inhibitors support a role 
of PDGFRα and PDGFRß in cancer and liver injury states such as fibrosis and cirrhosis 13, 102. 
PDGFRs are co-targeted by several small molecule pharmacologic agents such as imatinib, 
sunitinib, and sorafenib, which are multi-tyrosine kinase inhibitors each targeting a discrete set of 
tyrosine kinases 103.  
Many multi-TKIs that target PDGFRs appear to have activity against both α and ß isoforms 
93, 104, 105. As such, it is often difficult to delineate whether specific effects of these inhibitors stem 
from inhibition of PDGFRα, PDGFRß, or both receptors. Nevertheless, preclinical and clinical 
studies of multi-TKIs provide important evidence that PDGFRα is a potential therapeutic target in 
cancer. Imatinib has shown activity in gastrointestinal stromal tumors (GISTs), which do not 
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express mutations in c-KIT. This activity is likely due to demonstrated inhibition of PDGFRα 
which is mutated in many GISTs with normal c-KIT 106 and shares adjacent chromosomal location 
on human chromosome 4 as well as close amino acid homology with c-kit. Sorafenib, a multikinase 
inhibitor targeting Raf, VEGFRs, and PDGFRα/ß, is currently the only chemotherapeutic which 
has been shown to be effective in the treatment of HCC 12, 13. Sorafenib has also been shown to 
have beneficial effects in animal models of hepatic fibrosis and portal hypertension. Partial portal 
vein ligation (PPVL) in rats, a model of portal hypertension, showed a decrease in portal pressure 
and splanchnic inflammation as well as a decrease in TGF-ß, TGF-ßR1, and TIMP2 potentially 
leading to reduced fibrogenesis 107. Sorafenib also reduced intrahepatic fibrosis, inflammation, and 
neovascularization in rats undergoing BDL.  
A major impetus for the development of PDGFR inhibitors stems from their role in 
angiogenesis, as described in the preceding sections. Rats subjected to PPVL experienced 
decreased splanchnic neovascularization, pericyte coverage of new vessels, portal pressure, 
superior mesenteric artery blood flow and resistance when treated with a combination of VEGFR 
inhibitor Rapamycin and PDGFR inhibitor Gleevec compared to treatment with either agent alone 
108. Beneficial effects of combined VEGF/PDGF signaling inhibition in portal hypertension are 
supported by subsequent studies showing improved hemodynamics in PPVL rats treated with 
Sorafenib 109 
1.8.3 A Note on the Rationale for PDGFRα –Specific Targeting Inhibitors 
The development of specific and potent inhibitors such as Olaratumab that are already in clinical 
use, may present therapeutic and safety advantages 110, 111 due to reduction in off-target effects that 
allow for higher dosing. For instance, Olaratumab shows around 100-fold increased effect on 
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PDGF-mediated cell proliferation compared to the multi-tyrosine kinase inhibitor Imatinib 112. 
This potential for reduced side effects is particularly relevant when considering that the current 
multi-TKIs that co-target PDGF receptors and have shown anti-hepatic fibrosis activity are 
metabolized by cytochrome P450 (CYP450) enzymes in the liver and are poorly tolerated by 
patients. Hepatotoxicity is a major limiting factor in the use of these agents – especially those who 
already have liver dysfunction113. The prospects for the therapeutic application of Olaratumab and 
other PDGFRα –specific inhibitors will be further discussed in Chapter 5, incorporating a 
discussion of the relevant data included in the intervening chapters.  
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2.0  PDGFRα LOCALIZATION AND SIGNALING IN MURINE LIVER 
DURING CHRONIC LIVER INJURY 
Due to unresolved questions regarding the cellular origin of PDGFRα in hepatic fibrosis (see 
Section 1.7.4), we sought to examine the cellular localization of PDGFRα in chronically injured 
murine livers using co-immunofluorescence confocal microscopy. In the following sections, we 
present data supporting the expression of active PDGFRα signaling in murine livers following 
chronic liver injury, and specifically examine the presence (or absence) of this receptor in 
hepatocytes, cholangiocytes, sinusoidal endothelial cells, HSCs, and myofibroblasts.  
2.1 PDGF SIGNALING STATUS IN CHRONIC LIVER INJURY 
To examine the relevance of PDGF signaling in chronic liver injury, we utilized two well-
characterized models of chronic liver injury: repeated CCl4 injections and BDL. These models are 
described in detail in Section1.2 above. In assessing whether PDGFRα may play a functional role 
in the progression of chronic liver injury, we tested its expression as well as the expression of 
associated ligands in the presence of chronic CCL4-induced liver injury.  
Following 4 week CCL4 liver injury, we saw distinct increases in PDGFRα as well as 
PDGF-A, and PDGF-C ligands in whole liver lysates (Fig. 4A). This increase in expression was 
further pronounced at the 8 week CCl4 liver injury timepoint which is consistent with increased 
numbers of activated HSCs and myofibroblasts associated with advanced fibrotic liver injury 
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represented by the 8 week time course. Similarly, we also see a corresponding upregulation of 
PDGFRß – a well-known marker of HSCs.  
 
Figure 4: PDGFRα Signaling is Upregulated During Chronic Liver Injury. (A) PDGFRα expression as well as 
ligands of PDGFRα (PDGF-A and PDGF-C) are progressively upregulated at 4 weeks and 8 weeks of CCl4-induced 
liver injury in parallel with PDGFRß compared with corn oil injected controls. (B) Similar upregulation of PDGFRα 
is observed in mice after BDL compared to sham-operated control animals. In addition, increases in activating 
PDGFRα phosphorylation is detected at both Y742 and Y572/574. (C) PDGFRα upregulation is observed in human 




To determine whether PDGFRα activity was also upregulated in cholestatic liver injury, 
we examined its expression in murine livers 5 days and 14 days post-BDL. Compared to sham-
operated control animals, post-BDL murine livers had increased levels of PDGFRα as well as 
phosphorylated PDGFRα at signaling tyrosine residue Y742 (Fig. 4B). Furthermore, analysis of 
PDGFRα expression in liver tissue from patients with primary biliary cirrhosis (PBC) revealed 
elevations in several individuals compared to normal liver control (Fig. 4C), providing evidence 
of PDGFRα signaling involvement in human chronic liver disease. Based on this evidence, we 
concluded that PDGFRα signaling was involved in both early and advanced hepatic fibrosis, and 
involved in both chronic hepatotoxic (CCL4) and cholestatic (BDL) liver injury.  
2.2 PDGFRα LOCALIZATION DURING CHRONIC LIVER INJURY 
In light of evidence that PDGFRα signaling was upregulated in whole liver lysates of chronically 
injured murine and human livers, we sought to determine the specific cell types expressing 
PDGFRα during chronic liver injury to inform our efforts to generate genetic knockout murine 
models and to infer potential efficacy and consequences of therapeutic PDGFRα inhibition. Based 
on the ambiguity of PDGFRα expression in various PC and NPC cell populations (reviewed in 
Section 1.7.4), we examined the potential co-localization of cell markers for multiple liver cell 
types involved in the progression of hepatic fibrosis using both CCl4 and BDL models of chronic 
liver injury.  
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2.2.1 PDGFRα Expression in Parenchymal Cells of Fibrotic Liver 
Epithelial (parenchymal) cells of the liver include hepatocytes and cholangiocytes, which are both 
derived from endoderm-derived fetal hepatoblasts during liver development. In addition to playing 
important roles in hepatic growth and regeneration, parenchymal liver cells play an important role 
in the wound healing fibrotic response of the injured liver – including the release of pro-fibrotic 





Figure 5: Absence of PDGFRα in Hepatocytes and Cholangiocytes following Cholestatic Liver Injury. PDGFRα 
co-immunofluorescence with either (A) epithelial marker E-Cadherin (hepatocytes, cholangiocytes) or (B) 
cholangiocyte marker EpCAM showed no co-localization at 5 days or 14 days post-BDL injury. 
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In order to determine whether PDGFRα is expressed in parenchymal cells following 
chronic liver injury, we performed co-immunofluorescence analysis of PDGFRα with the 
epithelial marker E-cadherin and cholangiocyte marker EpCAM in post-BDL or sham-operated 
murine livers at 5 days and 14 days post-surgery (Fig. 5). No co-localization of PDGFRα with 
either marker was observed, suggesting that PDGFRα is not expressed in either hepatocytes or 
cholangiocytes following cholestatic liver injury. In contrast, co-immunofluorescence of PDGFRα 
and E-cadherin in CCL4-injured murine livers revealed a subset of pericentral hepatocytes which 
were positive for both markers (Fig. 6).  
 
Figure 6: PDGFRα Co-localization in Pericentral Hepatocytes during CCl4 Injury. PDGFRα expression was 
detected in a subpopulation of E-Cadherin-positive pericentral hepatocytes (arrows) in murine livers following 4 
weeks of CCl4-induced chronic liver injury. 
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2.2.2 PDGFRα Expression in Non-Parenchymal Cells of Fibrotic Livers 
Non-parenchymal cells of the liver include HSCs, Kupffer cells, sinusoidal endothelial cells 
(SECs), and other cell types that affect the progression and outcome of hepatic fibrosis (refer to 
section 1.3 for details). Several studies have shown evidence suggesting the presence of PDGFRα 
in HSCs68 and SECs (refer to Section 1.7.4).  To assess whether PDGFRα is expressed in SECs, 
we performed co-immunofluorescence of PDGFRα and LYVE-1 in murine livers following either 
CCl4 (Fig. 7A) or BDL-induced (Fig. 7B) liver injury.  In CCl4-treated murine livers, distinct 
separation between PDGFRα and LYVE-1 was observed suggesting relative absence of PDGFRα 
in SECs in the setting of toxic liver injury. Interestingly, we observed closer proximity of PDGFRα 
and LYVE-1 in co-immunofluorescence of post-BDL murine livers (Fig. 7B). To interrogate 
potential overlap between PDGFRα and LYVE-1 more closely, we examined high resolution serial 
confocal images (1µm step size) of post-BDL murine livers which showed PDGFRα cells closely 
adherent to – but distinct from – LYVE-1 positive cells (Fig. 7C).  
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Figure 7: PDGFRα is not Expressed in Sinusoidal Endothelial Cells during Chronic Liver Injury. (A) 
Representative co-immunofluorescence images in wildtype mice show no co-localization of PDGFRα in LYVE-1 
positive sinusoidal endothelial cells (SECs). (B) Co-immunofluorescence images in wildtype mice following BDL 
showed ambiguous overlap of PDGFRα in LYVE-1 positive SECs. (C) Absence of co-localization was determined 




Figure 8: PDGFRα Co-localization in Hepatic Stellate Cells during Chronic Liver Injury. Confocal 
immunofluorescence images of murine livers following 8 week CCl4, 16 day DDC, or 14 day BDL show PDGFRα 
expression co-localized to desmin, an established marker of HSCs. Non-treated (NT) livers are shown for comparison. 




Figure 9: PDGFRα Co-localization in Myofibroblasts during Chronic Liver Injury. Confocal immunofluorescence 
images of murine livers following 8 week CCl4, 16 day DDC, or 14 day BDL show PDGFRα expression co-localized 
to αSMA, an established marker of myofibroblasts. Non-treated (NT) livers are shown for comparison. Scale bars 
represent 100µm length. 
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The spindular morphology and close proximity of PDGFRα-positive cells to LYVE-1 
positive SECs suggested that PDGFRα positive cells may be HSCs. In order to confirm this, we 
performed co-immunofluorescence of PDGFRα with the HSC marker desmin (Fig. 8A) as well as 
the myofibroblast marker αSMA (Fig. 8B). Confocal immunofluorescence imaging showed close 
co-localization of PDGFRα with both markers in CCL4, BDL, and DDC diet-induced chronic liver 
injury. Of particular note, PDGFRα was expressed in desmin-positive HSCs in non-injured (NT) 
livers at baseline while maintaining distinct separation from αSMA. Together, these findings 
suggest the presence of PDGFRα in quiescent and activated HSCs as well as myofibroblasts.  
2.3 PDGFRα LOSS IN HEPATOCYTES DOES NOT AFFECT HEPATIC FIBROSIS 
2.3.1 PDGFRα Loss in Epithelial Cells does not Affect Hepatic Fibrosis 
Based on our findings that a subset of pericentral hepatocytes may express PDGFRα following 
CCl4-induced liver injury (Fig. 6), we sought to determine whether PDGFRα loss in epithelial cells 
would affect the outcome of chronic liver injury in vivo. To this end, we have generated 
hepatocyte-specific Pdgfra-/- mice by crossing floxed Pdgfra animals with mice expressing 
Albumin promoter-driven (Alb-Cre) or Foxa3 promoter-driven (Foxa3-Cre) Cre recombinase. 
Foxa3 is a member of the Foxa gene family of forkhead box containing transcription factors which 
plays an important role in early liver specification in conjunction with Foxa1 and Foxa2 to open 
compacted chromatin regions containing liver-specific regulatory regions in the developing 
foregut endoderm114. Since hepatoblasts originate from foregut endoderm, Foxa3-cre 
recombination is expected to cause floxed gene excision in both hepatocytes and cholangiocytes115. 
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Albumin - a more advanced marker of hepatocyte differentiation - is expressed in bipotential 
hepatoblasts along with other hepatocyte and biliary epithelial cell associated genes115. Our lab has 
published numerous studies using both Foxa3-Cre and Albumin-cre mediated recombination of 
floxed genes116, 117 .  
 
Figure 10: PDGFRα Expression is Retained in FoxA3-Cre Pdgfra-/- Livers. PDGFRα expression is upregulated 
following 4 weeks of CCl4-induced liver injury, but is not consistently downregulated in Foxa3-Cre Pdgfra-/- animals. 
 
The resultant Foxa3-Cre Pdgfra-/- mice showed no substantial reduction of PDGFRα in 
whole liver lysates (Fig. 10) following CCl4-induced liver injury. In addition, these mice did not 
show changes in overall fibrosis as assessed by Picrosirius Red staining of liver sections as well 
as αSMA immunohistochemistry (Fig. 11A,B). Hepatocellular injury was assessed using serum 
markers for liver injury including ALT and AST, however both Foxa3-Cre Pdgfra-/- and littermate 
controls showed similar levels of injury induction following CCl4 (Fig. 11C).  Furthermore, no 
difference in hepatocyte proliferation/regeneration was observed as indicated by similar levels of 
PCNA immunohistochemistry (Fig.11A,B). Based on these findings, we conclude that PDGFRα 
expression in pericentral hepatocytes following toxic liver injury is not a significant contributor to 
the propagation or recovery from hepatic fibrosis – either through an effect on hepatocyte-death 
driven fibrogenesis or hepatocellular regeneration. Similar results were seen in Alb-Cre Pdgfra-/- 
animal cohorts following CCl4-mediated chronic liver injury (data not shown).  
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Figure 11: FoxA3 Pdgfra-/- Mice Show No Change in Hepatic Fibrosis or Hepatocellular Injury During CCl4 
Injury. Sirius red staining, αSMA, and PCNA immunohistochemistry of liver sections from 4 week (A) and 8 week 
(B) CCl4-treated mice show no changes in Foxa3-Cre Pdgfra-/- (KO) mice compared to littermate controls (WT). (C) 
Serum liver function tests including ALT, AST, and ALP are similar in KO and WT controls following 4 weeks and 
8 weeks of CCl4-induced liver injury. 
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2.4 DISCUSSION: IMPLICATIONS OF PDGFRα EXPRESSION AND NULL 
FUNCTIONALITY IN HEPATOCYTES 
Specific RTK expression in multiple cell types is an important factor to consider in the 
development of any prospective targeted RTK inhibition during chronic liver injury. Different 
resident cell populations play potentially antagonistic pro- or anti-fibrotic roles in the setting of 
chronic liver injury62 and it is therefore conceivable the biologic endpoints of PDGFRα signaling 
(ie survival, proliferation) may contribute to injury progression in specific cells (ex: activated 
HSCs/myofibroblasts) while ameliorating injury in others (ex: hepatocytes). Precluding the 
availability of clinically viable HSC-targeted drug delivery, non-specific effects of RTK inhibition 
must be carefully considered. This is especially relevant in cases of chronic liver injury, in which 
hepatotoxicity of CYP450-metabolized drugs is exacerbated by decreased liver function. For many 
clinically approved RTK inhibitors, hepatotoxicity is the major limiting factor in their utilization113 
– providing a major impetus for the development of targeted RTK inhibition (see Section 5.2).  
While studies have shown that PDGFRα is expressed in HSCs68, studies of PDGFRα 
localization in other cell types in the liver has not previously been undertaken. In this chapter, we 
explored the expression of PDGFRα and its localization in two commonly utilized models of 
chronic liver injury to show its specific expression in a subset of pericentral hepatocytes and 
HSCs/myofibroblasts. Importantly, we rule out the possibility of PDGFRα expression in two cell 
populations relevant to chronic liver injury: cholangiocytes (in post-BDL livers) and SECs (both 
CCl4- and BDL-induced liver injury).  
Through the characterization of two models of hepatocyte-targeting PDGFRα loss (Foxa3-
Cre and Alb-Cre), we show that PDGFRα expression in a subset of peri-central hepatocytes does 
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not contribute to the progression of hepatic fibrosis during CCl4-mediated liver injury. This data 
confirms the absence of potential exacerbation of liver injury occurring from off-target PDGFRα 
loss/inhibition in hepatocytes, which could conceivably affect hepatocyte survival and 
proliferation – thereby worsening the outcome of chronic liver injury.  
Lastly, we are the first to confirm through high resolution confocal immunofluorescence 
co-localization imaging that PDGFRα is expressed in desmin-positive HSCs and αSMA-positive 
myofibroblasts in fibrotic liver sections. Based on these findings, we proceed to study the 
functional and mechanistic effects of PDGFRα inhibition in human HSCs in vitro (Chapter 3), as 
well as the pathophysiological consequences of PDGFRα loss in HSCs in multiple mouse models 
of chronic liver injury (Chapter 4).  
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3.0  PDGFRα CONTRIBUTES TO HUMAN HEPATIC STELLATE CELL 
PROLIFERATION AND MIGRATION 
In the previous chapter, we showed evidence that PDGFRα is expressed in both HSCs and 
myofibroblasts. In this chapter, we examine the role of PDGFRα in human HSCs and show that 
selective inhibition of PDGFRα with Olaratumab inhibits HSC proliferation and migration in vitro, 
but not pro-fibrotic gene expression. We show that these cell functions are differentially mediated 
by either exogenous or autocrine PDGF stimulation, and demonstrate the involvement of multiple 
downstream signaling pathways through analysis of phosphorylation of key signaling mediators 
involved in cell proliferation and migration including Erk1/2, p38, Akt, mTOR, FAK, and CrkII/L. 
During the process of liver injury, activated HSCs undergo a process of transdifferentiation 
towards a myofibroblast phenotype characterized by increased proliferation as well as altered gene 
transcription118. During this process, HSCs become motile and migrate to the sites of injury and 
inflammation guided by chemotactic stimuli such as growth factors like PDGFs, TGFß1, and type 
I collagen119-121.  In the setting of chronic liver injury, HSCs continue to migrate through hepatic 
lobule to the areas of injury and facilitate the progression of hepatic fibrosis122.  
The downstream signaling targets of PDGF-induced cellular activity are diverse and affect 
multiple cell functions. Among these targets are mitogen activated protein kinases such as Erk1/2 
and p38 which are central in the activation, proliferation, and migration of HSCs123-127. Factors 
such as Akt are common targets of PDGF signaling and have been demonstrated to function 
downstream of FAK - which plays a dual role in cell adhesion as well as PDGF-induced HSC 
proliferation128. Another functionally versatile signaling kinase is mTOR which is active in 
cellular processes associated with proliferation129 and migration130, 131. Our findings are also 
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consistent with studies showing that mTOR inhibition may attenuate experimental hepatic 
fibrosis25, potentially through reduction in proliferation and migration of activated HSCs. Adaptor 
proteins also play an important function in PDGF signaling exemplified by CrkII and Crk-like 
(CrkL), whose formation of a stabile complex with PDGFRα is one of the few identified 
distinctions between downstream effectors of PDGFRα and PDGFRß44, 132, 133. 
While the cellular function and downstream signaling mediators of PDGFRß signaling in 
HSCs have been extensively studied134-136, the precise role and contribution of PDGFRα in these 
cells has not been adequately elucidated137. Olaratumab (LY3012207, IMC-3G3, Eli-Lilly) is a 
humanized monoclonal antibody that targets PDGFRα with high potency and specificity and has 
been utilized in both preclinical and clinical studies112, 138-141. 
3.1 PDGFRα EXPRESSION IN HUMAN HEPATIC STELLATE CELLS 
In order to identify suitable HSCs for studies of PDGFRα, we examined its expression and 
activation in primary human hepatic stellate cells (HHSteCs) and LX-2, an immortalized HSC line. 
While PDGFRß was present in both cell types, expression of PDGFRα was more profound in 
HHSteCs (Fig. 12A). Furthermore, increased PDGFRα phosphorylation in response to PDGF-BB 
stimulation was also evident (Fig. 12A). LX-2 cells also showed PDGFRα phosphorylation in 
response to PDGF-BB, albeit to a lesser extent (Fig. 12A). Therefore, due to greater basal PDGFRα 
expression in HHSteCs and activation in response to the highly mitogenic and well-characterized 
pro-fibrotic ligand PDGF-BB, we opt to use these cells as a representative model of PDGFRα-





Figure 12: PDGFRα Expression and Activity in Hepatic Stellate Cells. (A) HHSteC and LX-2 cells showed 
differential expression of PDGFRα at baseline and corresponding increase in phosphorylated receptor following 
PDGF-BB (10ng/mL) treatment for 2 minutes. (B) HHSteCs stimulated with PDGF-AA (10ng/mL) for the indicated 
time periods show increased PDGFRα phosphorylation at Y742, Y849, and Y572/574. Associated downstream 
signaling mediators Akt and PKC also showed increased phosphorylation in response to PDGF-AA treatment. 
 
 
To assess if PDGFRα is functional in HHSteCs, these cells were treated with PDGFRα-
specific ligand PDGF-AA. This led to phosphorylation of PDGFRα at key tyrosine signaling 
residues (Fig. 12B). Furthermore, PDGF-AA treatment induced phosphorylation of downstream 
Akt and PKC (Fig. 12B).  
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To block PDGFRα, we employed the fully human anti-PDGFRα antibody Olaratumab 110, 
111. To validate efficacy and specificity of Olaratumab, ELISA-based cell free binding assay was 
performed. Olaratumab showed a dose-dependent binding to immobilized PDGFRα extracellular 
domain (ECD) (data not shown). Furthermore, the antibody concentration required for 50% 
maximum binding to PDGFRα ECD was calculated to be around 0.06 nM as also reported 
previously 139.  Olaratumab did not cross-react with a human PDGFRß ECD (data not shown). 
3.2 CONTRIBUTION OF PDGFRα SIGNALING TO HUMAN HSC 
PROLIFERATION 
3.2.1 PDGF Treatment Induces PDGFRα-dependent HHSteC Proliferation, but not Pro-
Fibrotic Gene Expression 
PDGF-BB signaling through PDGFRß plays a well-known central role in processes associated 
with HSC activation including proliferation and transdifferentiation to an activated myofibroblast 
state accompanied by the expression of pro-fibrogenic genes. However, the specific contribution 
of PDGFRα in these processes is unknown. To test the contribution of PDGFRα to HSC 
proliferation, we used alamarBlue cell viability assay following 24-hour exposure to PDGF-AA 
and PDGF-BB in the presence of PDGFRα-specific blocker Olaratumab or control IgG (Fig. 13A). 
We observed an increase in HHSteC proliferation in response to PDGF-AA and PDGF-BB when 
compared to non-treated (NT) controls. While Olaratumab alone was insufficient to affect HHSteC 
proliferation (Fig. 13A, B), incubation of these cells with Olaratumab in the presence of either 
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exogenous PDGF-AA or PDGF-BB resulted in a decrease in proliferation comparable or greater 
than that of Mitomycin C - a known inhibitor of DNA synthesis (Fig. 13A). 
Since HSC activation from a quiescent state is associated with increased expression of 
transcriptional targets including genes for structural extracellular matrix proteins (ex: COL1A1, 
FN1), cytokines (ex: TGFB1), neural markers (ex: SYP), and the contractile filament alpha smooth 
muscle actin (ACTA2), we next examined any effect of Olaratumab on pro-fibrotic gene 
expression. Olaratumab treatment for 24 hours led to no significant change in expression of any 
of these genes (Fig. 13C). To determine if the absence of PDGF was responsible for the lack of 
effect of Olaratumab on HHSteC activation, we also examined gene expression of the above-
mentioned targets following PDGF-AA or PDGF-BB exposure. Neither exogenous PDGF-AA or 















































Figure 13: PDGFRα Signaling Contributes to HHSteC Proliferation, but not Activation, in the Presence of 
Exogenous PDGF Stimulation. (A) Proliferation of HHSteCs was measured using alamarBlue dye following a 24-
hour incubation with PDGF-AA, PDGF-BB, Olaratumab, or IgG at the indicated concentrations. PDGF-AA and 
PDGF-BB induced significant proliferation of HHSteCs. HHSteCs were also exposed simultaneously to PDGF and 
Olaratumab, PDGF and IgG, or PDGF and mitomycin C (DNA synthesis inhibitor). Both Olaratumab and mitomycin 
C caused a reduction in PDGF-induced proliferation compared to IgG control. (B) PDGFRα inhibition using 
Olaratumab tested over 24 hours at various plating densities showed no significant change in proliferation compared 
to IgG-treated controls. (C) RT-PCR shows no significant changes in expression of ACTA2, TGFB1, COL1A1, FN1, 
or SYP in HHSteCs following Olaratumab treatment at multiple concentrations. TGFβ1 (2ng/mL) treatment was 
included as a positive control. All assays were performed in triplicates and results are normalized to their respective 




3.2.2 Olaratumab inhibits PDGF-BB mediated HSC proliferation through blockade of 
PDGFRα and downstream signaling 
In light of our findings that PDGFRα signaling contributes to HHSteC proliferation in the presence 
of exogenous PDGF ligands, we sought to determine the downstream signaling that is enhanced 
by PDGF ligand and blocked by Olaratumab treatment. In order to assess the most physiologically 
relevant signaling pathways involved, we tested the effect of Olaratumab in the presence of PDGF-
BB: a non-selective isoform of PDGF with a central role in HSC mitogenesis, chemotaxis, and 
activation during hepatic fibrosis21, 120, 142. HHSteCs were pre-treated with Olaratumab (300nM) 
or human IgG (300nM) for 30 minutes prior to exposure to PDGF-BB for various times (range 5 
minutes to 6 hours). 
PDGF-BB treatment led to increased phosphorylation of PDGFRα at all phosphorylation 
sites for which phospho-specific antibodies were available (Fig. 14A,B). Phosphorylation of 
PDGFRα in HHSteC cells in response to PDGF-BB was readily evident at all sites within 5 
minutes of treatment and peaked at 30 minutes with gradual decrease at 2 and 6 hours. Olaratumab 
pre-treatment of HHSteCs led to notable decreases in phosphorylation of PDGFRα at multiple 
tyrosine residues including Y754, Y849, Y762, and Y1018 (Fig. 14A,B). In contrast, Y742 and 
Y572/574 were unaffected.   
We next examined downstream effectors of PDGFRα associated with PDGF-induced 
proliferation such as Erk1/2 126, p38 124, FAK 128, Akt and mTOR 143, using phospho-specific 
antibodies including T202/Y204 for Erk1/2, T180/Y182 for p38 MAPK, Y397/Y576/Y577/Y925 
for FAK, S473 for Akt, and S2448/S2481 for mTOR. PDGF-BB treatment increased 
phosphorylation of Erk1/2, p38 MAPK, Akt, mTOR and FAK as compared  
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Figure 14: Olaratumab Inhibits PDGFRα Activation and Downstream Proliferative Signaling Mediators  
in HHSteCs in the Presence of Exogenous PDGF Stimulation. (A, B) HHSteCs were pretreated with either 
Olaratumab (300nM) or human IgG (300nM) for 30 minutes prior to PDGF-BB (10ng/mL) exposure for the indicated 
time periods. Representative western blots show decrease in phosphorylation of tyrosine signaling residues in 
PDGFRα in cells pretreated with Olaratumab including Y754, Y762, Y849, and Y1018, but not at Y742 and 
Y572/574. (C, D) Representative western blots show decreased phosphorylation of p38 MAPK (T180/Y182), FAK 
(Y397, Y576/Y577, Y925), Akt (Ser473), and mTOR (Ser2448, Ser2481) after PDGFRα blockade with Olaratumab 
(300nM) prior to PDGF-BB (10ng/ml) treatment. (E) Decreased phosphorylation of Erk1/2 (T202/Y204) and 
downstream transcription factor Elk1 (Ser383) was also observed.  Ponceau staining is included as a loading control. 
All Western blots were repeated twice on lysates from experimental conditions that were performed in triplicate and 
pooled for analysis. 
 
to non-treated cells. The peak phosphorylation of Erk and p38 MAPK occurred at 15 minutes 
followed by a gradual decrease up to 6 hours after PDGF-BB (Fig. 14C-E). While earlier time 
points were unchanged, a notable decrease in Erk1/2 phosphorylation was evident at 2-6 hours in 
the Olaratumab group (Fig. 14E, 15). Decreased phosphorylation of p38 MAPK was evident at 
only 30 minutes in the Olaratumab group (Fig. 14C-D, 15). Consistent with decreased 
phosphorylation of Erk1/2 and p38, we observed decreased phosphorylation of Elk-1, a known 
downstream target of Erk1/2 and p38 144, in Olaratumab pre-treated cells from 30 minutes to 6 
hours.  PDGF-BB treatment also led to increased FAK phosphorylation that peaked at 30 minutes 
to 2 hours. Olaratumab pre-treatment modestly affected FAK phosphorylation at Y397 at 15-30 
minutes and Y925 and Y576/577 at 2 hours (Fig. 14C-D, 15). PDGF-BB treatment led to a 
sustained mTOR phosphorylation at both S2481 and S2448, which was reduced by Olaratumab 
for up to 30 minutes (Fig. 14C-D, 15). Akt phosphorylation after PDGF-BB treatment was also 
sustained but peaked at 30 minutes to 2 hours (Figure 14C-D). Olaratumab decreased Akt 
phosphorylation at all time points with maximal affect at 2-6 hours (Fig. 14C-D, 15). 
Given Olaratumab’s selective inhibition of PDGFRα, as well as the universal binding of 
PDGF-BB to both PDGFRα and PDGFRβ receptors, our results provide evidence of an important 
and independent contribution of the PDGFRα in regulating multiple proliferative signaling 
pathways in human HSCs. 
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Figure 15:  Densitometric Quantification of Olaratumab-Mediated Changes in Protein Phosphorylation of 
HHSteCs in the Presence of Exogenous PDGF Stimulation. Densitometry of key phosphorylated protein changes 
from representative Western blots shown in Figure 3. Values are normalized to total protein levels and shown as the 
ratio of the signal of Olaratumab-treated HHSteCs to IgG-treated HHSteCs. The dashed line represents the value at 
which the relative phosphorylated protein signals of Olaratumab-treated HHSteCs and IgG-treated HHSteCs are equal.  
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3.3 CONTRIBUTION OF PDGFRα SIGNALING TO HUMAN HSC MIGRATION 
3.3.1 Olaratumab Inhibits HHSteC Migration Attributable to Autocrine Signaling 
PDGF has previously been reported to be a potent chemoattractant for HSCs - stimulating cell 
migration126, 145, 146. To examine whether PDGFRα signaling affects HSC migration, we 
performed transwell migration assays on HHSteCs exposed to Olaratumab, PDGF-BB, human 
IgG, or serum-free medium (NT). No significant change in cell migration following PDGF-BB 
treatment was observed - indicating that exogenous PDGF ligand stimulation did not substantially 
contribute to the migratory response of HHSteCs (Fig. 16A). In contrast, Olaratumab treatment 
alone significantly reduced HHSteC migration relative to IgG-treated controls (Fig. 16B).  
 The lack of migratory response to exogenous PDGF-BB and the simultaneous migratory 
inhibition to PDGFRα inhibition with Olaratumab suggests ongoing autocrine PDGFRα activation 
that may be contributing to migration of HHSteCs. HSC cell lines and primary HSCs typically 
undergo a process of activation towards a differentiated myofibroblast state as they are cultured in 
vitro 41 which is likely to induce autocrine secretion of activating ligands characteristic of 
myofibroblast transdifferentiation. To confirm this hypothesis, we analyzed PDGF gene 
expression of PDGF-A, -B, -C, and -D from RNA isolated from non-treated, low passage 
HHSteCs. RT-PCR analysis showed mRNA expression of all PDGFs in non-treated HHSteCs 
(Fig. 16C). We also observed presence of PDGF-BB protein in cell lysates of non-treated HHSteCs 
(Fig. 16D). Secretion of PDGF-BB, PDGF-CC, and PDGF-DD was also confirmed by WB 


























Figure 16: Olaratumab Inhibits Migration of HHSteCs in the Absence of Exogenous PDGF Ligand, Due to 
Autocrine Baseline Signaling. Representative images from HHSteC transwell migration assays and quantification 
(right panel) shows insignificant difference (NS) between no treatment (NT) versus PDGF-BB treatment. (B) 
Decreased HHSteC migration following Olaratumab versus IgG-treated controls after 3 hours relative to IgG-
treatment and quantified in right panel (p=0.0286). (C) RT-PCR of cDNA derived from non-treated HHSteCs (left 
lane) shows baseline expression of PDGFA, PDGFB, PDGFC, and PDGFD compared to HHSteC RNA in the absence 
of reverse transcriptase (middle lane) or primer only control (right lane) (separated due to non-inclusion of technical 
replicates). (D) Representative western blots of PDGF ligands detected in concentrated baseline HHSteC media after 
24 or 48 hours of serum starvation indicates autocrine secretion of PDGF-B, -C, and –D, but not PDGF-A.  
Concentrated supernatant from TGF-ß1-activated HHSteCs are shown for comparison. (E) Representative western 
blot shows PDGF-BB expression in non-treated HHSteC whole cell lysates and hepatocellular carcinoma (HCC) 
sample as a positive control. Ponceau staining is included as a loading control. 
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HHSteCs cultured for 24 or 48 hours (Fig. 16E).  Taken together these data indicate a role of 
autocrine PDGFRα signaling in HHSteC migration. 
3.3.2 Olaratumab Inhibits Baseline PDGFRα Activation in HHSteCs and Downstream 
Cell Motility Signaling 
Since Olaratumab affected HHSteC migration specifically in the absence of exogenous PDGF 
stimulation, we next assessed downstream signaling affected by Olaratumab in the absence of 
PDGF ligand to address the potential mechanism by which PDGFRα mediates cell migration. 
Whole cell lysates from HHSteCs treated with Olaratumab or IgG control for 30 minutes, 1 hour 
and 3 hours were examined for levels of phosphorylated PDGFRα and its downstream effectors. 
Lysates from HHSteCs treated with PDGF-BB for 30 minutes serve as a positive control (Fig. 17). 
We observed a notable decrease in PDGFRα phosphorylation at only Y762 and Y849, 
while other residues like Y754 remained unaffected following Olaratumab treatment (Fig. 17A, 
18). Relative decreases in phosphorylation of Erk1/2 at 1- and 3-hours, as well as p38 MAPK at 
all timepoints, were observed after Olaratumab treatment (Fig. 17B, 18). Reduced phosphorylation 
of Elk-1 is consistent with these findings as Elk-1 is a known downstream target of both Erk1/2 
and p38 MAPK (Fig. 17B) 144. Olaratumab treatment led to a decrease in mTOR phosphorylation 
at Serine 2448 especially at 30 minutes and ,1-hour time point but an increase in phosphorylation 
at Serine 2481 at all times (Fig. 5C). This suggests a shift away from mTOR complex 1 (mTORC1) 
147 - the rapamycin-sensitive form of mTORC whose inhibition has been previously shown to 




Figure 17: Olaratumab Inhibits Baseline PDGFRα Signaling in HHSteCs Along with Downstream Effectors. (A) 
Representative western blots from HHSteC treatment with Olaratumab (300nM) for the indicated time period showing 
decreased PDGFRα phosphorylation at Y762 and Y849 compared to IgG-treated controls. PDGF-BB treatment 
included as a positive control. (B) Representative western blots from HHSteC treatment with Olaratumab (300nM) 
for the indicated times showing decreased Erk and Elk-1 phosphorylation compared to IgG-treated controls. PDGF-
BB treatment serves as a positive control.  (C) Representative western blots show Olaratumab treatment decreased 
phosphorylation of mTOR at Ser2448 and increased phosphorylation at Ser2481. Olaratumab also decreased p38 
phosphorylation as well. (D) Representative western blots show Olaratumab treatment increased Abl expression and 
phosphorylation at Y412 and Y89 and increased phosphorylation at inhibitory tyrosine residues of CrkII (Y221) and 
CrkL (Y207). (E) Immunoprecipitation of HHSteC lysates using anti-CrkII shows increased binding of CrkII to both 
total PDGFRα and Phospho-PDGFRα Y762 following Olaratumab treatment. Ponceau staining is included as a 
loading control. All Western blots were repeated twice on lysates from experimental conditions that were performed 
in triplicate and pooled for analysis. 
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Figure 18: Densitometric Quantification of Olaratumab-Mediated Changes in Protein Phosphorylation in 
HHSteCs at Baseline. (A) Densitometry of key phosphorylated protein changes from representative Western blots 
shown in Figure 6. Values for each phosphorylated protein signal are normalized to total protein levels and shown as 
the ratio of the signal of Olaratumab-treated HHSteCs to IgG-treated HHSteCs. (B) c-Abl phosphorylated and total 
protein are represented separately to highlight the increase in both total and phosphorylated protein. The dashed line 
represents the value at which the relative phosphorylated protein signals of Olaratumab-treated HHSteCs and IgG-
treated HHSteCs are equal. 
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We next examined the effect of Olaratumab on signaling mediators more specifically 
associated with cell migration. CrkII and its isoform CrkL are signaling adaptor proteins that play 
an active role in actin reorganization associated with cell motility149. Phosphorylation of CrkII 
(Y221) and CrkL (Y207) by Abl kinase results in sequestration of SH2 and SH3 binding domains 
of Crk proteins leading to inhibition of downstream signal activation40. Olaratumab treatment of 
HHSteCs led to increased phosphorylation of both CrkII and CrkL, suggesting decreased binding 
activity of these adaptor proteins (Fig. 17D). Consistent with inhibition of Crk signaling we 
observe activation of Abl kinase, indicated by phosphorylation of Abl at Y412150 and Y89151, 152 
(Fig. 17D). The inhibition of Crk signaling downstream of PDGFRα inhibition is also consistent 
with the specific inhibition of PDGFRα phosphorylation at Y762 (Fig. 17A), which has been 
shown to be necessary for PDGF-dependent Crk signaling133. Although PDGFRα has been shown 
to bind directly to Crk proteins potentially leading to stabilization of a non-phosphorylated CrkII-
PDGFRα complex and prolonging the signaling activity of CrkII, we noted Olaratumab to strongly 
induce CrkII protein interaction to both total PDGFRα as well as Phospho-PDGFRα Y762 (Fig. 
17E). Thus, the overall basis of PDGFRα blockade on human HSC migration appears to be through 
a cumulative effect on modulation of Erk, p38 MAPK, mTORC1 and CrkII/CrkL. 
3.4 DISCUSSION: DISSECTING THE ROLE OF PDGFRα IN HUMAN HSCS 
The development of specific and potent inhibitors such as Olaratumab offers an opportunity to 
study exclusive PDGFRα function in human HSCs using a clinically viable therapeutic agent. 
Recently a phase II clinical trial for the use of Olaratumab in soft tissue sarcoma patients led to the 
FDA granting accelerated approval for this drug110, 111. In addition to its potential therapeutic 
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utility, Olaratumab also offers a means to study the specific signaling pathways activated by 
PDGFRα independent of PDGFRß. To our knowledge, our study is the first to directly examine 
the role of PDGFRα in human HSCs through pharmacologic inhibition of PDGFRα. Further, we 
examine the effect of PDGFRα-specific inhibition on downstream signaling mediators in vitro. 
Using the PDGFRα-specific inhibitor Olaratumab, we show that human hepatic stellate cells 
respond to exogenous or autocrine PDGFs in part through PDGFRα and specific downstream 
signaling to contribute to proliferation and migration, but not transdifferentiation to activated 
myofibroblasts (Fig. 13). 
After confirming the expression of PDGFRα co-localized to HSCs and activated 
myofibroblasts in multiple models of murine chronic liver injury (Chapter 2), we show that human 
HSCs respond to exogenous or autocrine PDGFs in part through PDGFRα-specific downstream 
signaling to contribute to proliferation and migration, but not pro-fibrotic gene expression (Fig. 
12). Baseline blockade of PDGFRα signaling in HHSteCs affected migration but not proliferation 
or pro-fibrotic gene expression. Exogenous PDGF-BB did not induce migration or pro-fibrotic 
gene expression but induced HHSteC proliferation, which was suppressed by PDGFRα blockade. 
These findings point to distinct biological outcomes of autocrine versus paracrine PDGF-
BB/PDGFRα signaling axis. A possible explanation is a distinct cellular response to dose of ligand 
available at baseline versus during exogenous treatment. Suffice to say that both distinct and 
common signaling events were associated with the two biological outcomes of PDGFRα blockade. 
The major translational significance of the current study is the use of a clinically relevant biological 
in human HSCs and its effectiveness in suppressing two key processes of HSCs for treatment of 
hepatic fibrosis, which remains a major unmet clinical need. 
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Due to the central role of PDGF signaling in HSC proliferation, we tested the effect of 
PDGF as well as Olaratumab on HHSteC proliferation in vitro. We found that both PDGF-AA and 
PDGF-BB promote HHSteC proliferation, which was inhibited by Olaratumab. PDGFRß plays an 
important role in HSC proliferation. Studies in rat HSCs have shown PDGFRß to have higher 
mitogenic activity than PDGFRα 69, 70. Since PDGF-BB is the predominant mitogen for HSCs 
during hepatic fibrosis, we wanted to address the relative contribution of PDGFRα towards HSC 
proliferation. In our study, Olaratumab blockade prior to PDGF-BB treatment of HSCs led to 
decreased HSC proliferation that was associated with inhibition of several phosphorylation sites 
in PDGFRα and of multiple downstream effectors including Erk1/2, p38, Elk-1, FAK, mTOR and 
Akt. In particular, Erk1/2, Elk-1, FAK, and Akt showed sustained reduction in activating 
phosphorylation after Olaratumab-mediated PDGFRα inhibition. Erk1/2 is known for its role in 
HSC proliferation 126, while its downstream target Elk-1 promotes gene expression associated with 
proliferation153 and migration144. FAK has been shown to serve as a sensor for the detection of 
integrin-mediated binding to ECM and simultaneously acts as a signaling node for PDGF-induced 
proliferation in HSCs via FAK/PI3K/Akt pathway 128. FAK also promotes Erk-mediated cell 
proliferation through phosphorylation at Y925 and Y397, two of the tyrosine residues affected by 
Olaratumab 154. Akt affects cell proliferation through diverse sets of mechanisms 155, 156. In 
contrast, the role of p38 in HSC proliferation is more ambiguous as inhibition of p38 in primary 
rat HSCs reduced proliferation157 while p38 was necessary for PPARδ - induced LX-2 
proliferation158. Our findings corroborate the results of the latter study, which may reflect a 
species-specific difference in the role of p38 in activated HSCs.  
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Figure 19: Proposed Effect of PDGFRα Blockade on HSC Migration and Proliferation through Inhibition of 
Specific Downstream Signaling. (A) In response to PDGFRα activation by autocrine and/or exogenous PDGF, HSC 
proliferation and migration are induced through activation of FAK, Erk1/2, p38, Akt, mTOR, and CrkII/CrkL 
signaling. (B). Blockade of PDGFRα by Olaratumab decreases the above mentioned signaling mediators, with FAK, 
Erk1/2, mTOR and Akt impacting proliferation and Erk1/2, p38, CrkII/L, decreased mTORC1 and increased 
mTORC2 regulating migration. Decreases in signaling activity of downstream targets is represented by dashed arrows. 
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 It is important to note that PDGF-BB treatment led to an increase in phosphorylation of 
PDGFRα at Y754, which was decreased by Olaratumab. Y754 is an indicator of formation of 
PDGFRαß heterodimer159, suggesting that Olaratumab mediates part of its effect on HSC 
proliferation through the inhibition of heterodimer formation. However, since Olaratumab inhibits 
phosphorylation of other signaling residues of PDGFR (which are more specific for PDGFRα 
homodimer) in the presence of exogenous PDGF-BB, we conclude that there is a definite and 
unique contribution of PDGFRα to HSC proliferation through Erk1/2, Elk-1, FAK and Akt (Fig. 
14). A small increase in Erk1/2, Akt, mTOR, and FAK after initial Olaratumab treatment may be 
due to its potential transient and partial agonistic activity. 
It was intriguing to note that expression of fibrosis-associated genes did not show a 
response to Olaratumab or PDGF-AA treatment in HHSteCs, suggesting that PDGFRα may be 
dispensable in HSC pro-fibrotic gene induction. Together, these data suggest that PDGFRα in 
HSCs may have a more narrowly defined function than its counterpart PDGFRß, a finding 
consistent with earlier investigations showing less potent activation of HSCs as a result of 
PDGFRα signaling136, 160 as well as studies of rat HSCs showing that PDGFRß has higher 
mitogenic activity than PDGFRα161, 162. Notably, our studies do not preclude a ligand-independent 
contribution of PDGFRα signaling to HSC activation. This is particularly relevant in light of 
studies showing that PDGFRα is necessary for TGFß1-mediated SMAD activation following 
interaction and internalization of a PDGFRα monomer/TGFß Receptor II complex77. 
In our study, the Y762 residue of PDGFRα was one of the tyrosine residues specifically 
affected by Olaratumab treatment. This tyrosine residue has special significance because its 
phosphorylation has been shown to be necessary for the ability of PDGFRα directly bind the SH2 
domain of Crk133.  Indeed, one of the earliest substrate differences identified between PDGFRα 
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and PDGFRß was among the amino acids surrounding Y771 of PDGFRß and the homologous 
Y762 residue of PDGFRα163. Initially it was thought that out of the two PDGF receptor isoforms, 
only PDGFRα bound to Crk133. Later studies showed that PDGFRß bound to Crk as well, albeit in 
a much more transient nature - likely due to the relative inefficiency of Crk phosphorylation by 
PDGFRα compared to PDGFRß132, 149. The prolonged direct binding of PDGFRα to Crk proteins 
is considered to be one of the only major differences in signaling function between PDGFRα and 
PDGFRß44, underscoring the significance of our findings in the setting of PDGFRα-specific 
inhibition by Olaratumab.  
The prolonged binding of PDGFRα to Crk proteins is considered a major difference in 
signaling function between PDGFRα and PDGFRß 44. Upon phosphorylation of Y221 on CrkII, 
and Y207 on CrkL, their SH2 domain is sequestered, leading to inhibition of Crk activity 164. 
During its effect on cell migration, Olaratumab reduced phosphorylation of Y762-PDGFRα, which 
was associated with increased phosphorylation of CrkII and CrkL. Olaratumab treatment increased 
c-Abl activation as indicated by increased phosphorylation, which in turn is known to 
phosphorylate and inactivate CrkII/CrkL 40. The relatively stable interaction of CrkII/CrkL and 
PDGFRα, in contrast to rapid phosphorylation by PDGFRß, has been speculated to lead to 
prolonged activity of CrkII/CrkL, leading us to hypothesize that inhibition of Y762 
phosphorylation by Olaratumab may dissociate the Crk/PDGFRα complex and lead to early 
phosphorylation of CrkII/CrkL by another kinase like c-Abl 132.  Surprisingly, Olaratumab resulted 
in a dramatic increase in binding of CrkII to both total and Y762-phosphorylated PDGFRα. It is 
likely that Olaratumab-mediated enhanced phosphorylation and hence inhibition of Crk activity 
occurs despite enhanced PDGFRα-CrkII association. Further studies will be critical to uncover the 
precise mechanism by which Olaratumab alters CrkII/L phosphorylation.  
 72 
Migration of HSCs is an important mechanism of perpetuation of hepatic fibrosis. PDGF 
ligands, specifically PDGF-BB are known chemotactic stimuli for HSCs 142. We did not observe 
a significant increase in migration of HHSteCs following PDGF-BB treatment. However, 
HHSteCs expressed and secreted PDGF ligands at baseline, indicating potential autocrine 
PDGFRα signaling. Indeed, activation of HSCs as a result of cell culture is well-known in both 
primary 165, 166 and immortalized HSCs 167. Olaratumab blocked HHSteC migration, which was 
associated with decreased PDGFRα phosphorylation at Y762 and Y849. Among residues not 
affected was Y754, ruling out the role of PDGFRαß heterodimer in HSC migration. Previous 
studies have shown that PDGF-AA-specific for the PDGFRαα homodimer is not chemo-attractive 
for HSCs in contrast to other PDGF ligand dimers 119, 168. However, our study clearly shows a 
reproducible effect of PDGFRα inhibition on HHSteC migration, which was associated with 
notable decreases in phosphorylation of well-known mediators of HSC migration like Erk1/2 and 
p38 MAPK 169 and others like mTOR (Y2448) and Crk.  
Olaratumab treatment of HHSteCs in the setting of both exogenous PDGF and autocrine 
signaling shared a reduction in Erk1/2 as well as mTOR. However in contrast to mTOR 
phosphorylation changes in the presence of exogenous PDGF, we observed differential changes in 
mTOR phosphorylation suggestive of a shift away from mTOR complex 1 (mTORC1) signaling 
to mTOR complex 2 (mTORC2) signaling (Fig.17C)147. Due to the apparent association of 
autocrine PDGFRα activation with migratory signaling in HHSteCs, this may mean that mTORC1 
plays a more predominant downstream effector of PDGFRα. This finding is consistent with studies 
showing that mTOR inhibitors that primarily affect the rapamycin-sensitive mTORC1 have shown 
promise in reducing experimental fibrosis170-172 - including through reduced proliferation and 
migration of HSCs in hepatic fibrosis148. Of particular note, rapamycin has been demonstrated to 
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reduce PDGF-induced migration of HSCs in vitro143. Further studies will be needed in order to 
definitively assess the role of mTOR downstream of PDGFRα signaling in HSCs. 
Overall our study concludes that PDGFRα contributes to human HSC proliferation and 
migration independent of pro-fibrotic gene expression. These findings suggest that Olaratumab, 
alone or in combination, may have therapeutic activity in the pathogenesis of hepatic fibrosis.  
However, future research of potential therapeutic approaches aimed at inhibiting the PDGFRα 
pathway in in vivo models, including potential combinations, is unpredictable and would need to 
be performed prior to clinical investigation.   
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4.0  LOSS OF PDGFRα IN MICE AMELIORATES HEPATIC FIBROSIS 
DURING CHRONIC LIVER INJURY 
In the previous chapter, we provided evidence that PDGFRα is functionally important to 
mitogenesis and cell migration in human primary HSCs. Our next aim was to determine whether 
loss of PDGFRα in HSCs in vivo affected the progression of chronic liver injury. In order to 
address this question, we have acquired Lrat-cre mice from our collaborator Dr. Robert Schwabe 
at Columbia University173. Using this strain, we have generated a novel murine model of Cre-lox 
recombination using the promoter for lecithin retinyl acyl-transferase (Lrat) to drive Cre 
expression in floxed Pdgfra mice in a HSC-specific manner. By subjecting resulting LratCre 
Pdgfra knockout (Pdgfra-/-) animals and their wildtype littermate (WT) controls to multiple 
models of chronic liver injury, we sought to test the hypothesis that PDGFRα expression in HSCs 
contributes to the progression of hepatic fibrosis.  
4.1 BACKGROUND: PRINCIPLES AND DEVELOPMENT OF HSC-SPECIFIC 
TRANSGENE EXPRESSION IN MICE 
Animal models of chronic liver injury resulting in hepatic fibrosis and cirrhosis-like phenotypes 
(see Section 1.3) have developed in conjunction with advances in the identification of promoters 
driving transgene expression in quiescent and/or activated HSCs. Some of the promoters used to 
identify activated HSCs include components of promoters for collagen α-1(I), collagen α-2(I), and 
αSMA21. While effective, such promoters lead to targeted transgene expression only in 
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myofibroblasts and cells that have undergone a significant degree of activation. Due to the need to 
study factors contributing to HSC activation from a quiescent state in the non-injured liver, 
promoters targeting quiescent HSCs have also been widely used.  
With increasing evidence that the large majority of myofibroblasts arise from 
transdifferentiation of HSCs173, and due to the need to analyze the process of transdifferentiation 
of quiescent HSCs to activated HSCs and myofibroblasts, promoters targeting specific transgene 
expression in quiescent HSCs have become widely used in studies of hepatic fibrosis. The most 
prominent promoter used for targeting transgene expression in quiescent HSCs is glial fibrillary 
acidic protein (GFAP), an intermediate filament protein first discovered in astrocytes174. Despite 
the widespread use of GFAP promoter for HSC-targeted transgene expression, these models must 
be rigorously tested and validated for HSC-specific transgene expression, due to lineage tracing 
studies showing that the human or murine promoter for GFAP not reliably target HSCs and have 
robust cholangiocyte expression173.  
The search for more reliable promoters expressed specifically in non-activated HSCs led 
to the consideration of lecithin: retinol acyltransferase (Lrat). Lrat plays an important role in the 
formation of retinyl ester lipid droplets in HSCs which is necessary for the storage of retinoids 
(vitamin A and its metabolites) and is one of the primary characteristics of quiescent HSCs. In a 
seminal study demonstrating efficiency and specificity of Lrat promoter expression, Lrat-cre mice 
have been shown to express Cre in 99% of HSCs, and through fate tracing in toxic and cholestatic 
liver injury models, these HSCs were shown to give rise to 82-96% of myofibroblasts173. These 
studies, as well as findings from our own lab (unpublished) showing non-specifically transgene 
expression in GfapCre mice, have led us to use Lrat-Cre animals for the targeted expression of Cre 
transgene in HSCs.  
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4.2 VALIDATION STUDIES OF LRAT-CRE PDGFRα KO STRAIN 
4.2.1 Loss of PDGFRα in Liver Lysates of Lrat-Cre Pdgfra-/- Mice 
We have previously shown that PDGFRα is upregulated at the level of whole liver cell lysates 
following chronic liver injury in multiple models of chronic liver injury (Fig. 4). In order to 
confirm loss of PDGFRα expression in Lrat-Cre Pdgfra-/- mice, we examined whole liver lysates 
through Western blot and found that PDGFRα expression was lost or reduced in Lrat-Cre Pdgfra-
/- livers in representative samples from CCl4, BDL, and DDC models of liver injury (Fig.20A). 
The loss of nearly all PDGFRα expression in many Pdgfra-/- livers support the finding that 
PDGFRα is primarily expressed in HSCs and myofibroblasts, while the presence of residual 
PDGFRα expression in some Pdgfra-/- livers suggest possible expression of PDGFRα in 




Figure 20: LratCre Pdgfra-/- Mice show Reduced Total and HSC/Myofibroblast-specific PDGFRα following 
Chronic Liver Injury. (A) Representative Western blots showing reduction of total PDGFRα expression in whole 
liver lysates of Lrat-Cre Pdgfra-/- (KO) and littermate controls (WT). (B) Representative confocal 
immunofluorescence microscopy showing reduction in PDGFRα expression in desmin-positive HSCs of Lrat-Cre 
Pdgfra-/- mice following 4 week CCl4, 16 day DDC, or 14 day BDL chronic liver injury. Scale bar represents 100µm. 
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4.2.2 Loss of PDGFRα in HSCs and Myofibroblasts of Lrat-Cre Pdgfra-/-  Mice 
In order to more specifically confirm loss of PDGFRα expression in HSCs and myofibroblasts in 
Lrat-Cre Pdgfra-/- mice, we performed co-localization immunofluorescence confocal microscopy 
of PDGFRα with either desmin (HSCs) or αSMA (myofibroblasts) in CCl4, DDC, and BDL-
injured livers of Pdgfra-/- and WT mice (Fig.20B). In each condition, we saw clear loss of 
PDGFRα in desmin-positive and αSMA-positive cells in Pdgfra-/- animals compared to WT 
littermate controls.  
4.3 CHARACTERIZATION OF LRAT-CRE PDGFRα KO MICE 
4.3.1 Biliary Fibrosis is Unaffected in Lrat-Cre Pdgfra-/-  Mice Following Cholestatic 
Liver Injury 
We first examined the phenotype of Lrat-Cre Pdgfra-/- mice in two models of cholestatic liver 
injury to examine the effect of PDGFRα loss in biliary fibrosis. Specifically, we examined fibrosis 
at 5 days and 14 days post-BDL as well as following 16 days of DDC-supplemented diet. Though 
we observed a qualitative reduction in collagen deposition in Lrat-Cre Pdgfra-/- mice at both 5 
days post-BDL and 16 day DDC timepoints (Fig. 21A, C), this change was not significant when 
quantified under either condition. In addition, no changes in desmin or αSMA IHC was observed 
in any of the timepoints tested, including 14 day post-BDL (Fig. 21B). Collagen was quantified 
using polarized light microscopy for BDL samples. Collagen immunofluorescence was performed 
on DDC sections for quantification due to the detection of porphoryin plugs in brightfield and 
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polarized light microscopy which interfere with quantification. Based on these findings, we 
conclude that HSC-specific PDGFRα loss does not affect hepatic fibrosis in the setting of biliary 
injury.  
4.3.2 Reduced Hepatic Fibrosis in Lrat-Cre Pdgfra-/-  Mice Following Short Term 
Hepatotoxic Liver Injury 
In order to determine whether loss of PDGFRα in Lrat-Cre Pdgfra-/- mice affected the progression 
of hepatic fibrosis in hepatotoxic liver injury, we next assessed LratCre Pdgfra-/- mice following 
4 weeks or 8 weeks of CCl4-induced liver injury. We found that after 4 weeks of CCl4-induced 
liver injury, fibrosis was significantly reduced in Lrat-Cre Pdgfra-/- mice as assessed by 
quantification of Picrosirius red images taken with polarized light (brightfield images shown) (Fig. 
22A). These changes were also reflected in desmin immunohistochemistry showing a reduction of 
the total number of HSCs in LratCre Pdgfra-/- mice (Fig. 22A). In contrast, no changes in fibrosis 
was seen following 8 week CCl4 treatment (Fig. 22B). These findings suggest that PDGFRα does 
have an effect on hepatic fibrosis in hepatotoxic liver injury that is limited to early stages of fibrosis 





       
Figure 21: Biliary Fibrosis is Unaffected in LratCre Pdgfra-/- Mice following Cholestatic Liver Injury. Lrat-Cre 
Pdgfra-/- mice showed no significant change in fibrosis or HSC/myofibroblast population expansion as assessed by 
Sirius Red staining, desmin, and αSMA IHC. Biliary fibrosis was assessed at (A) 5 days and (B) 14 days post-BDL 
injury, as well as (C) 16 days DDC-induced liver injury. Quantification is shown. For DDC sections, collagen was 
quantified by immunofluorescence imaging. 
 
Notably, no change in αSMA immunohistochemistry was observed at either timepoint, indicating 
that HSC transdifferentiation to myofibroblast phenotype may not be affected by PDGFRα loss.  
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Figure 22: Lrat-Cre Pdgfra-/- Mice show Reduced Hepatic Fibrosis During Early, but not Advanced Hepatotoxic 
Liver Injury. (A) Lrat-Cre Pdgfra-/- mice showed reduced fibrosis as assessed by Sirius red staining and desmin IHC 
at 4 weeks CCl4-induced liver injury. No change in αSMA IHC was observed at this timepoint. (B) No change in 
hepatotoxic fibrosis was seen in Lrat-Cre Pdgfra-/- mice at the 8 week CCl4 timepoint.  Quantification of Sirius red 
collagen staining is shown. 
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4.3.3 Reduced Mid-Zonal Distribution of HSCs Following Biliary and Hepatotoxic Liver 
Injury 
Migration is an important function of activated HSCs which facilitates their ability to reach areas 
of liver injury and initiate the deposition of ECM associated with hepatic fibrosis. Despite the lack 
of significant changes in overall levels of fibrosis in BDL- and DDC-induced liver injury models, 
closer analysis of HSC distribution in these models revealed a distinct decrease in mid-zonal HSC 
distribution in Pdgfra-/- livers as observed by desmin IHC (Fig. 23). In the absence of changes in 
overall desmin IHC, these findings may reflect a reduction in the ability of HSCs to migrate in the 
setting of biliary fibrosis. These changes were also observed in Pdgfra-/- animals following CCl4-





Figure 23: Lrat-Cre Pdgfra-/- Mice show Reduced Mid-Zonal Distribution of HSCs Following Biliary and 
Hepatotoxic Liver Injury. Representative higher magnification images of desmin IHC-stained liver sections highlight 
reduced distribution of HSCs in mid-zonal areas in Lrat-Cre Pdgfra-/- livers compared to WT controls. Images 








4.3.4 Reduced Hepatocellular Injury and Increased HSC/Myofibroblast Cell Death in 
Lrat-Cre Pdgfra-/-  Mice Following CCl4 
Analysis of liver function tests (LFTs) in cholestatic models of liver injury (BDL and DDC) 
showed no significant difference in the level of hepatocellular injury as indicated by similar 
ALT/AST in Lrat-Cre Pdgfra-/- animals (Fig. 24). In addition, early fibrosis timepoints in CCl4 
injury model revealed similar levels of hepatocellular injury (indicated by ALT, AST) as well as 
cholangiocyte injury (ALP). Interestingly however, while serum ALT/AST values continued to 
progress in WT animals, ALT/AST values in Lrat-Cre Pdgfra-/- animals plateaued and stayed at 
a similar level to the 4 week-treated cohort (Fig. 25A). In order to further investigate the potential 
reason for this discrepancy, we examined hepatocyte regeneration by PCNA 
immunohistochemistry as well as relative levels of necrosis and apoptosis assessed by TUNEL 
staining of liver sections in Pdgfra-/- and WT animals. While we did not see an overall difference 
in the level of hepatocyte proliferation assessed by PCNA (data not shown), we did see an 
intriguing inverse relationship between TUNEL staining of pericentral hepatocytes and TUNEL 
staining of spindular-shaped HSCs between Pdgfra-/- and WT animals (Fig. 24B). Specifically, 
TUNEL staining of Lrat-Cre Pdgfra-/- liver sections showed generally fewer TUNEL positive 
hepatocytes but larger numbers of TUNEL positive HSCs. The latter finding suggests that 
PDGFRα may promote survival of activated HSCs or myofibroblasts in advanced hepatic fibrosis, 
and that loss of PDGFRα in these cells may adversely affect cell survival, leading to increased 
apoptosis/necrosis of HSCs. The finding that Lrat-Cre Pdgfra-/- animals possessed decreased 
TUNEL positive hepatocytes is consistent with a decrease in overall hepatocellular injury as 
indicated by lower ALT/AST values. In order to determine a possible cause for this discrepancy, 
we next examined inflammatory cell response in these animals.  
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Figure 24: Hepatocellular Injury Following BDL and DDC Unaffected in Lrat-Cre Pdgfra-/- Mice. Liver function 
tests from harvested animal serum were performed and showed insignificant differences in ALT, AST, ALP, total and 




Figure 25: Reduced Hepatocellular Injury and Increase HSC/Myofibroblast Cell Death in Lrat-Cre Pdgfra-/- Mice 
Following CCl4. (A) ALT and AST values in Lrat-Cre Pdgfra-/- remained stable between 4 weeks and 8 weeks of 
CCl4-induced liver injury and were significantly reduced at the 8 week timepoint compared to littermate controls. (B) 
TUNEL staining of Lrat-Cre Pdgfra-/- liver sections following 8 week CCl4-induced liver injury shows increased 
numbers of TUNEL positive HSCs/myofibroblasts (arrows) while lacking the robust levels of TUNEL positive 
pericentral hepatocytes (arrowheads) in comparison to littermate controls.   
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4.3.5 Increased Inflammatory Response and Hepatic Macrophage Infiltration in Lrat-Cre 
Pdgfra-/-   Mice Following Long Term CCl4-induced Injury 
To further elucidate the cause of reduced hepatocyte necrosis in Pdgfra-/- animals after 8 week 
CCl4-induced liver injury, we examined general measures of inflammation including CD45 
(leukocyte common antigen) and F4/80 (macrophage marker) immunohistochemistry. Despite 
reduced levels of fibrosis between WT and Pdgfra-/- animals at 4 week CCl4 liver injury, we saw 
no differences in either CD45 or F4/80 IHC at this timepoint (Fig. 26). In contrast, we saw a 
notable increase in both CD45 and F4/80 IHC in Pdgfra-/- animals at the 8 week CCl4 timepoint. 
Notably, the increase in both CD45 positive cells as well as F4/80 positive macrophages was 
primarily observed in fibrotic foci centered around pericentral regions. Since the major function 
of hepatic macrophages as part of the innate immune response is the clearance of cellular debris 
and apoptotic bodies, it is likely that the increased presence of macrophages in these regions leads 
to the relative reduction in necrotic hepatocytes in Pdgfra-/- animals at the 8 week CCl4 timepoint 
compared to littermate controls (previously shown in Fig. 25B). This finding is also consistent 











Figure 26: Increased Inflammatory Response and Hepatic Macrophage Infiltration in Lrat-Cre Pdgfra-/- Mice 
Following Long-Term CCl4-induced Injury: CD45 (A) and F4/80 (B) immunohistochemistry of liver sections from 
4 week and 8 week CCl4-treated Lrat-Cre Pdgfra-/- (KO) mice and littermate controls (WT) are shown. No change in 
CD45 positive or F4/80 positive cells is observed at 4 week timepoint between KO and WT mice but an increase in 
both cell types is observed in KO mice at 8 week timepoint.  
4.4 DISCUSSION: DOES PDGFRα PLAY A SUBSTANTIAL ROLE IN HEPATIC 
FIBROSIS AND LIVER INJURY? 
Our study is the first to examine the loss of PDGFRα in a HSC-specific manner using the HSC-
specific promoter for Lrat, in order to direct Cre expression for the excision of floxed Pdgfra in a 
highly specific and efficient manner. This model is rigorously validated by confocal co-
localization immunofluorescence to show loss of PDGFRα in HSCs/myofibroblasts of KO 
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animals. Previous studies have identified PDGFRα expression in HSCs and shown their 
upregulation in HSCs following CCl4-induced chronic liver injury as well as reduced fibrosis in 
mice with heterozygous expression of PDGFRα68. In this study, mice heterozygous for PDGFRα 
were used due to the fact that global Pdgfra null animals are embryonically lethal. While 
heterozygous loss of PDGFRα prevents the developmental defects associated with global PDGFRα 
loss, these animals do not lose PDGFRα in a cell-specific manner and by definition would likely 
retain some PDGFRα expression HSCs. Our study provides proof of principle that PDGFRα loss 
specifically in HSCs ameliorates early CCl4-induced fibrosis in vivo.  In addition, we utilize 
multiple models of chronic liver injury including CCl4, BDL, and DDC, in order to 
comprehensively test the validity of our findings across different modes of chronic liver injury.  
Studies of chronic liver injury on the mechanisms of hepatic fibrosis progression have 
focused on the potential for therapeutic intervention to prevent or reverse fibrosis. The ultimate 
therapeutic goal of such intervention is to prevent the progression of hepatic fibrosis to end stage 
liver diseases such as cirrhosis or HCC, which accompany devastating clinical consequences. 
There is however established clinical and pre-clinical evidence that advanced fibrosis and cirrhosis 
are less reversible (or irreversible) compared to earlier stages of fibrosis4-6. In our study, we 
observed decreased hepatic fibrosis in Lrat-Cre Pdgfra-/- animals following 4 week CCl4-induced 
liver injury but not after 8 weeks of CCl4 (Fig. 22). This finding is consistent with a contributory 
role of PDGFRα with the initiation and early perpetuation of hepatic fibrosis and suggests that 
while PDGFRα inhibition may play an important role in ameliorating early fibrosis, it is not likely 
to be sufficient as a monotherapy for the complete prevention or reversion of advanced fibrosis.   
Furthermore, Lrat-Cre Pdgfra-/- animals did not show a significant reduction in fibrosis in 
either models of biliary fibrosis (BDL, DDC), even when biliary fibrosis was assessed at relatively 
 91 
early liver injury timepoints (5 days post-BDL, 16 days DDC). A potential explanation for the 
discrepancy in findings between hepatotoxic liver injury (CCl4) and cholestatic liver injury (BDL, 
DDC) is the presence of a small population of portal fibroblasts which does not express Lrat. These 
cells have been previously identified as a precursor contributing to the myofibroblast population 
in biliary fibrosis and consequently may retain PDGFRα expression in our model173. Mederacke 
et al found that while the majority of myofibroblasts originated from Lrat-tdTomato-expressing 
cells in both toxic (CCl4, TAA) and cholestatic (BDL, DDC) forms of liver injury, the overlap 
between tdTomato expression and myofibroblast marker αSMA was considerably less in 
cholestatic liver injury (82-85%) compared to toxic liver injury (93-96%) models. 
Earlier in this document we outlined the conflicted evidence for a major role of PDGF 
signaling in portal fibroblast fibrogenicity (see section 1.7.3). Further studies will be needed to 
determine whether PDGFRα is expressed specifically in the portal fibroblast subpopulation, and 
whether potential retention of PDGFRα in this population can help to supplement the 
myofibroblast supply in a compensatory manner in Lrat-Cre Pdgfra-/- animals during biliary 
fibrosis. If so, the discrepancy in our findings in hepatotoxic and biliary fibrosis may reflect a 
limitation of the Lrat-Cre model of transgene expression, rather than a redundant or 
inconsequential role of PDGFRα in biliary fibrosis. In this regard, pharmacologic inhibition of 
PDGFRα in cholestatic liver injury models may be useful to circumvent these issues. 
Another limitation of our current model is the inability to distinguish in vivo contributions 
of PDGFRα signaling in HSCs compared to transdifferentiated myofibroblasts. Studies have 
shown a differential response and sensitivity to pro- or anti-fibrogenic growth factors between 
HSCs and myofibroblasts. For example, cultured rat HSCs showed reduced TGFß1-induced 
proliferation inhibition in their transdifferentiated (myofibroblast-like) form – despite similar 
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levels of TGFß receptor expression in both forms- due to changes in relative ligand-binding 
affinity of TGFß receptors175. Similarly, there is evidence that PDGF-induced proliferation in 
HSCs may be an earlier event in the progression of HSC transdifferentiation. Evidence that HSC 
proliferation in response to PDGF is an early response of HSCs in cholestatic liver injury176. Based 
on this evidence, it is possible that higher numbers of myofibroblasts present in more advanced 
stages of liver fibrosis (represented in our study by the 8 week CCl4 cohorts) may be less dependent 
on PDGFRα signaling for the perpetuation of fibrosis. 
In Chapter 3 we showed that PDGFRα contributes to proliferation and migration of human 
HSCs, while lacking a direct effect on the expression of fibrosis-associated genes including 
ACTA2 (αSMA). These findings provide a functional explanation for how loss of PDGFRα in 
vivo may alter the progression of hepatic fibrosis. For example, our finding that desmin IHC is 
reduced in Pdgfra-/- livers following 4 week CCl4 injury supports the notion of impaired HSC 
proliferation (Fig. 22A). Increased HSC death at this timepoint is unlikely to explain the reduction 
in desmin positivity, as Pdgfra-/- and WT livers showed similar low levels of TUNEL staining at 
this timepoint (data not shown). Also consistent with our findings in human HSCs, no changes in 
αSMA IHC were seen under any conditions, suggesting a lack of an effect of PDGFRα on 
myofibroblast transdifferentiation. 
Examination of the mid-zonal regions of Pdgfra-/- livers following desmin IHC also 
suggests a possible effect of PDGFRα loss on HSC migration. Migration of HSCs presumably 
facilitates the movement of activated HSCs towards areas of injury and inflammation and is likely 
to contribute the formation of characteristic “bridging fibrosis” seen in advanced hepatic fibrosis. 
Based on these assumptions, we posit that a reduction in the mid-zonal distribution of HSCs in 
Pdgfra-/- livers (Fig. 23) may be partially due to a defect in HSC migration – particularly in biliary 
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fibrosis where overall HSC proliferation appears to be unaffected due to similar levels of desmin 
positivity (Fig. 21). These findings are consistent with our findings that Olaratumab inhibits 
migration in human HSCs (Fig. 16). At this time however we cannot rule out the possibility that 
the observed changes in mid-zonal HSC distribution are primarily driven by anti-proliferative or 
anti-survival effects of PDGFRα loss – especially in CCl4-induced liver injury. Future studies 
incorporating HSC isolation and subsequent migration assays will be required to show whether 
migration of HSCs is significantly affected in Lrat-Cre Pdgfra-/- mice.  
ALT and AST values are the most commonly used clinical surrogate measures of 
hepatocyte death upon which liver injury and disease is screened and monitored in patients. During 
CCl4-mediated liver injury, we saw a remarkable plateau of ALT and AST between the 4 week 
and 8 week timepoints in which ALT/AST levels did not increase in Lrat-Cre Pdgfra-/- animals 
compared to littermate controls. Consistent with these changes in ALT/AST, we observed 
decreased TUNEL-positive hepatocytes in Pdgfra-/- animals representing an overall reduced level 
of hepatotoxicity compared to littermate controls. Of particular interest was a concomitant increase 
in TUNEL-positive HSCs in Pdgfra-/- mice at this timepoint.  
Apoptosis is a known mechanism of myofibroblast reduction during regression of 
fibrosis22. While PDGFRα is known to play a role in cell survival in mesenchymal cell types177 
against apoptotic stimuli, studies thus far have not reported a contribution of PDGF receptors in 
promoting HSC survival independent from their effect on HSC transdifferentiation to 
myofibroblasts during liver injury. For example, PDGFRß siRNA does not induce apoptosis of 
HSCs isolated from rats post-BDL178. In another study of activated HSCs isolated from rat livers 
post-BDL, PDGF-AB did not reduce rat HSC apoptosis in response to serum deprivation179. 
Therefore, our findings may indicate a novel and distinct pro-survival function of PDGFRα 
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signaling in HSCs and suggest that loss of PDGFRα in myofibroblasts of Lrat-Cre Pdgfra-/- mice 
may make these cells more vulnerable to premature apoptosis. One way in which the effect of 
PDGFRα signaling on HSC/myofibroblast survival may be through TGFß-conferred anti-
apoptosis which has previously been reported in rat HSCs in vitro180, 181. This could conceivably 
result from the PDGF ligand-independent interactions of PDGFRα and internalized TGFß receptor 
I/TGFß Receptor II heterodimer complexes following binding to TGFß which has been 
demonstrated in human HSCs77.  
While PDGF is known to promote myofibroblast transdifferentiation from HSCs, we posit 
that increased resistance to apoptosis as a result of myofibroblast transdifferentiation182 is not the 
driving force behind the increase in TUNEL positive HSCs/myofibroblasts in Pdgfra -/- animals 
at 8 weeks CCl4. This is because we did not observe a change total number of transdifferentiated 
myofibroblasts as assessed by αSMA IHC. This finding is consistent with our previous findings in 
primary human HSCs in vitro, in which we have shown that inhibition of PDGFRα using 
Olaratumab did not have an effect on the expression of fibrosis-associated gene expression (Fig. 
13).   
The substantial increase in F4/80 positive cells in Pdgfra-/- animals centered at the 
pericentral hepatocyte foci of injury at 8 weeks of CCl4-induced injury suggest that hepatic 
macrophages may be driving an accelerated immune-mediated clearance of apoptotic/necrotic 
hepatocytes and cell debris in these animals. We posit that this effect may be responsible for the 
overall reduction in liver injury seen at this timepoint as reflected by ALT/AST serum values. 
Immune-mediated clearance of cell debris resulting from hepatocyte apoptosis/necrosis is 
considered an important step for effective hepatocyte regeneration. Furthermore, it has previously 
been shown that hepatic macrophage depletion in rats following CCl4-mediated injury has 
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differential effects during different periods of injury and recovery – with macrophage depletion 
early in liver injury alleviating fibrosis and macrophage depletion during CCl4 recovery resulting 
in slower recovery and decreased fibrosis regression183. This dual nature of hepatic macrophages 
on chronic liver injury may explain the discrepancy between our findings in Pdgfra-/- mice fed 
DDC-supplemented diet for 16 days – a short term injury course in which fibrosis and 
inflammation were positively correlated – and those treated with CCl4 for 8 weeks where 
inflammation was negatively correlated with injury outcome. Therefore, loss of PDGFRα in 
HSCs/myofibroblasts and its effects on survival may indirectly promote a beneficial inflammatory 
response in later stages of chronic liver injury that improves clearance of hepatocyte debris and 
ameliorates further progression of liver injury. This proposed phenomenon is illustrated in Figure 
27.  
Our model is naturally limited by the lack of inducibility of Cre transgene expression in 
HSCs. This limitation precludes us from drawing clear distinctions between the effect of PDGFRα 
loss in quiescent HSCs compared to activated HSCs and fully transdifferentiated myofibroblasts. 
Nevertheless, our study provides clear evidence of a substantial contribution of PDGFRα to the 
progression of hepatic fibrosis. Future studies will be needed to confirm whether PDGFRα 
inhibition in a therapeutic manner will be effective in reversing the course of fibrosis (see section 
5.2 below).   
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Figure 27: Proposed Timeline of the Impact of PDGFRα Loss in HSCs During CCl4-induced Chronic Liver Injury: 
(1) During early stages of liver fibrosis (represented at 4 weeks of CCl4 administration), reduction in HSCs is observed 
as well as decreased hepatic fibrosis – likely as a result of impaired HSC proliferation and migration. (2) As chronic 
liver injury progresses (represented at 8 weeks of CCl4 administration), HSCs/myofibroblasts in Pdgfra-/- animals 
undergo increased levels of cell death which is hypothesized to be the result of decreased response to PDGF survival 
signals. (3) The presence of increased inflammatory cells and hepatic macrophages in Pdgfra-/- animals may be the 
result of pro-inflammatory cell debris and chemokines released from dying HSCs/myofibroblasts. (4) The resulting 
increased influx of hepatic macrophages in Pdgfra-/- animals results in improved clearing of necrotic hepatocytes near 
injury foci, ameliorating overall liver injury. This improvement in hepatocellular injury is detected as reduced levels 
of ALT/AST in Lrat-Cre Pdgfra-/- serum following 8 weeks of CCl4 compared to littermate controls (Pdgfra+/+). 
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5.0  DISCUSSION AND FUTURE STUDIES 
5.1 PDGFRα AND PDGFRß IN HEPATIC STELLATE CELLS: 
INTERCHANGEABLE OR DISCRETE FUNCTIONS? 
PDGFRα and PDGFRß have mostly overlapping downstream signaling pathways and functions 
and respond to similar ligands as described in Section 1.4. Due to these structural and functional 
similarities, it is reasonable to question whether their functions in HSCs are distinct and whether 
one isoform is able to sufficiently compensate for the other in the event of receptor loss or 
inhibition. This question has therapeutic implications and will need to be answered if isoform-
specific inhibitors such as Olaratumab are to be considered for therapeutic use in chronic liver 
injury. While our current studies do not explicitly compare PDGFRß-specific loss or inhibition in 
HSCs, we do show that PDGFRα inhibition in vitro and downregulation in vivo has a distinct 
functional contribution in HSCs separate from expression of PDGFRß. 
Recent studies examining the effects of PDGFRß loss in HSCs in murine CCl4 and BDL 
injury models support the notion that PDGFRß is a major contributor to the fibrogenic potential of 
HSCs135. In comparing the findings of this study with our study in vivo, it is apparent that both 
PDGFRß and PDGFRα promote HSC proliferation in chronic liver injury – as early fibrosis 
timepoints in each of these studies (1 week and 4 weeks, respectively) show decreased fibrosis and 
HSC numbers as assessed by Sirius red staining and desmin IHC. In contrast, PDGFRα loss in our 
model did not result in changes in αSMA IHC while PDGFRß deficient mice showed a significant 
reduction of this measure of HSC activation.  
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Furthermore, the level of fibrosis reduction achieved in these studies suggest that PDGFRß 
is a more predominant mediator of fibrosis than PDGFRα. Nevertheless, our data indicate that 
PDGFRα plays a role in the progression of early fibrosis as well as recovery from injury in later 
fibrosis. Combined with our studies of Olaratumab-mediated PDGFRα inhibition in human 
primary HSCs showing that PDGFRα inhibition did not result in changes of fibrosis-associated 
gene expression, our studies point towards a divergence in function between PDGFRα and 
PDGFRß where PDGFRß contributes to both HSC proliferation and activation, while PDGFRα 
contributes to proliferation only.  
 One interesting and unanswered question is the relative contributions of PDGFRα and 
PDGFRß to the survival of HSCs/myofibroblasts in the presence of fibrosis resolution. As 
discussed above in Section 4.4, our data points to a potential pro-survival effect of PDGFRα which 
is lost in HSCs of Pdgfra-/- mice following 8 weeks of CCl4-induced liver injury. Since loss of 
PDGFRα at this timepoint had no effect on total or activated HSC numbers measured by desmin 
or αSMA IHC, respectively, this change cannot be accounted for by increased HSC proliferation 
or myofibroblast transdifferentiation. In contrast, the effect of PDGFRß loss in vivo on HSC 
apoptosis/necrosis has not yet been investigated, though studies of isolated rat HSCs following 
BDL suggest that siRNA-mediated loss of PDGFRß does not affect HSC survival178.  
Interestingly, while Kocabayoglu et al135 investigated different timepoints of CCl4-induced 
injury (1 week and 6 weeks) compared to our study (4 weeks and 8 weeks), a similar pattern of 
ALT/AST reduction was seen in both of these models. Specifically, while PDGFRß loss and 
PDGFRα loss at early timepoints (1 week and 4 weeks, respectively) did not result in a difference 
between ALT/AST values between knockout and littermate controls, a similar reduction in 
ALT/AST was seen at the later timepoints assessed in these studies (6 weeks and 8 weeks, 
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respectively). This similar trend is remarkable because it suggests that inhibition of PDGFRα or 
PDGFRß individually may improve the outcome of advanced liver injury, even while expression 
of its sister isoform receptor in these HSCs is retained. In other words, the beneficial effects of one 
PDGF receptor isoform loss in vivo does not appear to be averted by compensatory signaling of 
its sister isoform – at least at the timepoints tested in these studies.  
These findings are also noteworthy because they suggest that an improvement in liver 
injury outcome may not be contingent upon reduction of overall hepatic fibrosis. While it is 
generally agreed that hepatic fibrosis is a pathogenic process that broadly correlates with liver 
dysfunction and hepatotoxicity, it remains unclear to what extent fibrotic changes in the liver drive 
chronic liver injury and loss of function, rather than vice versa. On this point – while the resolution 
of hepatic fibrosis has been a major goal of our study and the many preceding it, it has not 
conclusively been shown that resolution of hepatic fibrosis alone will resolve chronic liver injury 
in patients without abatement of the source of injury and hepatocellular repair/regeneration. For 
these reasons, we consider PDGFRα alone or in combination with PDGFRß to be viable 
therapeutic targets that warrant further study and consideration in the treatment of chronic liver 
injury.  
5.2 PROSPECTS FOR PDGFRα-SPECIFIC INHIBITORS IN HEPATIC FIBROSIS 
The development of specific inhibitors of PDGFRα has shown promising results in preclinical and 
clinical studies. The use of Olaratumab in our studies in human HSCs (Chapter 3) as well as the 
therapeutic effect of PDGFRα loss in mice during chronic liver injury (Chapter 4) provides 
important proof-of-concept evidence of the potential effectiveness of specifically targeting 
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PDGFRα signaling in chronic liver conditions such as fibrosis, cirrhosis and HCC (discussed 
further in next section). While multi-TKI small molecules targeting multiple receptors and 
pathways have therapeutic effects, they may also be prone to a lower therapeutic index due to 
toxicity from bystander receptor activation. Inhibitory monoclonal antibodies targeting single 
receptors have several advantages including higher specificity, lower off-target tissue toxicity, and 
the use of higher drug doses with lower risk of developing drug resistance due to sub-therapeutic 
dosing110, 111. For instance, Olaratumab shows approximately 100-fold increased effect on PDGF-
mediated cell proliferation compared to the multi-TKI Imatinib (Gleevec) 112. In addition, 
antibodies generally have a longer half-life (necessitating less frequent dosing) and less variation 
in clearance among individuals than most small molecule therapies184. 
Current multi-TKIs that co-target PDGF receptors and have shown anti-fibrotic activity in 
the liver are metabolized by CYP450 enzymes of hepatocytes and are poorly tolerated by patients. 
For these agents, hepatotoxicity remains a major limiting factor for effective dosing – a problem 
which is exacerbated in patients with chronic liver injury who are likely to have decreased liver 
dysfunction at baseline113. Currently Sorafenib – the only moleculary therapeutic approved for 
treatment of HCC - has been shown to have major concerns for liver toxicity at relatively low 
doses185 
We have previously shown that Olaratumab decreases proliferation of various hepatoma 
and HCC cell lines 53. In addition, our previous studies in ß-catenin KO mice suggest that PDGFRα 
may be an important co-therapeutic target in ß-catenin inhibition of HCC 186. Based on the high 
frequency of PDGFRα overexpression 53, 187 and the relative success of Sorafenib (a PDGFRα co-
inhibitor) in human HCCs, blockade of PDGFRα signaling may indeed have therapeutic value in 
liver cancer. In addition to Olaratumab, other PDGFRα-specific inhibitors are available for use in 
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preclinical models such as the murine PDGFRα inhibitor APA5 188-191. Combined with the 
potential for genetic modulation of PDGFRα demonstrated in the data presented here and in 
previous studies 52, 68, an abundance of potential preclinical models for PDGFRα modulation are 
available and await future investigation in liver regeneration, injury, and cancer.  
The development of specific inhibitors of PDGFRα has shown promising results in 
preclinical and clinical studies. Olaratumab is a unique, directed antibody therapy that exclusively 
targets PDGFRα and is currently being tested in clinical trials112.  Olaratumab has been shown to 
have anti-tumor properties in several preclinical studies including lung cancer xenografts138, 
glioblastoma and leiomyosarcoma xenografts139, and ovarian carcinoma140 . The use of highly-
specific small molecule inhibitors also allows the close study of functions and signaling pathways 
attributable to specific receptors – an endeavor which is obscured by the use of multi-tyrosine 
kinase inhibitors. As an example, the multi-kinase inhibitor sorafenib which has shown some 
promise in a preclinical context for the treatment of hepatic fibrosis remains not fully understood 
in its mechanism of action.  
Though our studies suggest that PDGFRα plays a limited role in the perpetuation of hepatic 
fibrosis – with effects on collagen deposition limited to early stages of hepatic fibrosis (Fig. 21-
22) – the observed effects on overall hepatocellular injury and inflammation (Fig. 25-26) suggest 
that PDGFRα inhibition may have therapeutic activity that is not directly tied to levels of fibrosis. 
Studies closely examining in vivo loss or inhibition of PDGFRα following the establishment of 
fibrosis, and during the resolution of chronic liver injury, will be critical to determine its future 
utility as an anti-fibrotic therapy. This is discussed in further detail below (Section 5.4). 
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5.3 BEYOND FIBROSIS: STUDIES OF PDGFRα INHIBITION IN LIVER CANCER 
In patients with cirrhosis, hyperplastic hepatocytes succumb to increasing genomic instability as a 
result of unrelenting necrosis and regeneration in the face of chronic liver injury. In a subset of 
these patients, these regenerative hepatocytes eventually form dysplastic nodules and give rise to 
HCC 10. HCC is the most common type of liver cancer with a 5 year survival rate of only 8.9% in 
the U.S.A. 10 Currently non-palliative treatments for cirrhosis and HCC are limited to 
radiofrequency ablation, transarterial chemoembolization, resection, and liver transplantation 11. 
The latter is the most effective but is associated with high morbidity, cost, life-long 
immunosuppressive therapy and a shortage of donor organs. Thus, there is a strong need for the 
identification of new therapeutic targets associated with the pathogenesis of these conditions as 
well as effective methods of inhibition. 
Studies from our lab and others suggest a role of PDGFRα dysregulation in 
hepatocarcinogenesis (full review in 192). We have previously shown that the majority of human 
HCCs overexpress PDGFRα and that a subset of these tumors also show an upregulation of PDGF-
AA and PDGF-CC53. This study also demonstrates that several human and rat cell lines of 
hepatoma and HCC also exhibit increased expression and activation of PDGFRα, and in vitro 
inhibition of PDGFRα in these human cell lines using Olaratumab led to significant decreases in 
DNA synthesis and cell survival. PDGFRα overexpression was also detected in 46/63 (73.0%) 
patients who did not undergo neoadjuvant chemo/radiotherapy 187. In this study, a significant 
clinical correlation was found between vascular invasion in resected HCCs that overexpress 
PDGFRα as well as those that overexpress PDGFRß compared to those that did not. In addition, 
the co-expression of PDGFRα, PDGFRß, and VEGF was identified by multivariate analysis to be 
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an independent prognostic factor of disease-free and overall survival in this cohort. Furthermore, 
PDGFRA is upregulated in K19 positive HCCs from patients, which are associated with increased 
tumor size, microvascular invasion, metastasis, and poor differentiation 193. Lastly, a study found 
high intratumoral expression of PDGFRα and PDGFRß in a small subset of HCCs, which were 
independently associated with poor overall survival 194. The seeming discrepancy between the 
number of patients expressing ‘high’ levels of PDGFRα in this study compared to other studies in 
which the majority of patients overexpress PDGFRα 53, 187 may be explained by the categorization 
of patients into ‘high’ or ‘low’ expression groups, in which only tissues staining with the highest 
intensity on a five tier scale were categorized as ‘high’ – rather than direct comparison of PDGFRα 
upregulation compared to adjacent normal liver tissue.  
Findings in patients are corroborated in preclinical animal models of HCC. Mice lacking 
the secreted proteoglycan decorin - a tumor suppressor inhibiting both EGFR and the hepatocyte 
growth factor receptor Met - have dysregulated PDGFRα signaling in TAA-induced 
hepatocarcinogenesis leading to more severe cirrhosis and HCC 85.  This was possibly due to 
impaired sequestration of secreted PDGF ligands by decorin in the ECM and increased production 
of PDGF.  
These findings suggest that unregulated PDGFRα signaling is pathogenic and may promote 
hepatocarcinogenesis. The number of studies suggesting a role of PDGFRα in promoting 
hepatocarcinogenesis has been a driving impetus for the further study of specific roles of PDGFRα 
in liver cancer. Some of the potential modes of action and regulation of PDGFRα in HCC are 
discussed in the following sections.  
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5.3.1 Potential Roles of PDGFRα in Tumor Biology: Modulation of Angiogenesis and 
Hypoxic Response in Chronic Liver Injury and Cancer 
HCC is a highly-vascularized tumor for which PDGFRs represent potential alternative targets to 
supplement traditional VEGFR inhibitors. While PDGFRß has been the most well documented 
PDGF receptor for angiogenic effects including vessel stability 195 and maturation 196, there is 
evidence for a role of PDGFRα in angiogenesis as well.  
Studies have shown that specific PDGFRα blockade results in the downregulation of 
angiogenic factors which may be an important mode of growth inhibition in tumors 141. 
Furthermore PDGFRα is a co-target of several anti-angiogenic drugs 197, some with anti-fibrogenic 
effects 198. PDGFRα expression in endothelial cells (ECs) 199, 200 and vascular smooth muscle cells 
201, as well as liver sinusoidal ECs 64 has been reported.  In addition, the presence of PDGFRα in 
liver EC in liver cancer is strongly supported by findings in HCC (described below) indicating its 
upregulation in pathologic angiogenesis.  
There is substantial evidence that PDGFRα signaling in HCC is associated with metastasis 
and tumor progression, mediated at least in part by pathologic angiogenesis. PDGFRα is 
overexpressed in EC of HCC associated w/ high metastatic potential in a murine xenograft model 
and increased recurrence of HCC in patients 93. In fact, PDGFRα is one of the only known tumor 
EC markers in HCC that correlates with metastasis. Higher tumor recurrence rate and lower 
survival in human HCCs expressing high PDGFRA was reaffirmed in a study by Zhu et al 202. This 
study also employed a murine xenograft model using an HCC cell line and transfected human 
umbilical vein endothelial cells (HUVECs) to show evidence that tumor progression may be the 
result of dysregulation of PDGFRA by BRCA1, which is in turn regulated by microRNA 146a 
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(MiR-146a). This study shows a potential regulatory mechanism of PDGFRα expression in ECs 
of HCC, and introduces a new potential therapeutic target upstream of PDGFRα (MiR-146a). 
While the precise role of PDGFRα/PDGFA signaling in HCC progression is unknown, 
studies indicate that this signaling arm is likely to be an important escape pathway for pathologic 
angiogenesis in the setting of HCC. One murine HCC model showed increased PDGFA expression 
in the liver following drug resistance development to IFN-alpha 203, an antiviral with known anti-
angiogenic effects 204. This is consistent with evidence that tumor fibroblasts may become resistant 
to anti-VEGF therapy through the expression of PDGF-C 94. Furthermore, it has been shown that 
VEGFA can activate PDGFRα and PDGFRß, likely due to the close homology between PDGFR 
and VEGFR 205. Thus, PDGFRα signaling may be an important alternative therapeutic target in 
addition to VEGFRs, and may explain why sorafenib (a multi-tyrosine kinase receptor inhibitor 
targeting VEGFRs and PDGFRs) is currently the only clinically approved targeted therapy for 
HCC 12, 13.  
PDGF signaling is also important for communication between HSCs and ECs of the liver 
during angiogenesis to coordinate the formation and stabilization of neovessels. Co-transplantation 
of Ras-transformed hepatocytes with myofibroblasts in a murine model of HCC enhances tumor 
growth in a PDGF-dependent manner 206. Studies in rats undergoing BDL demonstrate that PDGF-
BB promotes HSC-driven vascular tube formation through ephrinB2 signaling207. The authors in 
this study hypothesize that this phenomenon is responsible for a decrease in portal pressure in BDL 
rats following Imatinib treatment. Given the known expression of PDGFRα on HSCs 65, 68, and 
HCC-associated EC 93, it is possible that PDGFRα activation by PDGF ligands may play an active 
role in these processes.  
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Hypoxia is a well-known driver of pathologic angiogenesis. Though the specific response 
of PDGFRα in hypoxic liver tissue has not been reported, potential activity of this receptor can be 
gleaned from hypoxia-induced modulation of PDGF ligands, especially PDGF-A. PDGFA as well 
as PDGFB are downregulated in HIF-1α deficient mice, signifying a link between hypoxia and the 
release of these profibrogenic mediators 208. HIF-1α/ß in hepatocytes in vitro do not appear to 
significantly affect the production of PDGF-A or PDGF-B mRNA but, rather, promote other 
angiogenic factors including VEGF. Combined with this group’s previous findings in HIF-1α 
deficient mice, these data indicate that HIF-1 is regulating PDGF-A and –B expression in NPCs. 
HIF-2α is also shown to be a likely mediator of this effect 209. Investigation of PDGFR localization 
and activation in response to hypoxia will be an important complement to studies of HIF-induced 
ligand production in order to discern the precise effects of PDGFRs in hypoxic response and 
angiogenesis. 
5.4 FUTURE STUDIES 
Earlier in this document we outlined the conflicted evidence for a major role of PDGF signaling 
in portal fibroblast fibrogenicity (see section 1.7.3). One limitation of the murine model utilized in 
Chapter 4 is the presence of a small population of portal fibroblasts which do not express Lrat 
which have been previously identified as contributing to myofibroblasts and would retain PDGFRα 
expression in our model173. Mederacke et al found that while the majority of myofibroblasts 
originated from Lrat-Cre expressing tdTomato-expressing cells in both toxic (CCl4, TAA) and 
cholestatic (BDL, DDC) forms of liver injury, the overlap between tdTomato expression and 
myofibroblast marker αSMA was considerably less in cholestatic liver injury (82-85%) compared 
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to toxic liver injury (93-96%) models. This data mirrors our own findings in BDL and DDC in 
which some PDGFRα expression is retained in myofibroblasts of knockout animals (Fig. 20 and 
data not shown). Thus additional studies will be needed to determine if portal fibroblasts 
specifically express PDGFRα, and whether PDGF signaling affects their contribution to biliary 
fibrosis.  
Based on our findings described in Chapter 4 that PDGFRα may contribute to HSC 
survival, it remains to be answered whether PDGFRα inhibition will have beneficial effects on the 
resolution of fibrosis. In order to answer this question, we will assess levels of hepatic fibrosis, 
liver injury, and hepatocellular regeneration in a model of fibrosis resolution (8 weeks CCl4 
administration followed by 7 days recovery). Mechanisms of cell death will also need to be more 
closely examined to determine whether increased TUNEL positivity of HSCs/myofibroblasts is 
the result of apoptosis, necrosis, or necroptosis – a recently elucidated pathway of regulated 
necrosis210. 
Our current findings using Olaratumab to inhibit PDGFRα signaling in human HSCs in 
vitro, as well as our findings that early hepatic fibrosis is ameliorated in Lrat-Cre Pdgfra-/- mice, 
provides an important foundation for future studies of therapeutic PDGFRα inhibition in hepatic 
fibrosis. One approach synthesizing the strengths of the two approaches mentioned above is the 
therapeutic administration of PDGFRα inhibitor to in vivo models of chronic liver injury. The 
human-specific inhibitory nature of Olaratumab, as well as our inability to obtain sufficient 
quantities of murine-targeting PDGFRα-specific inhibitor precluded us from undertaking such a 
study at this time. However, such studies will be important in order to strengthen the findings 
outlined in this dissertation and to avoid influence of HSC-specific PDGFRα loss during normal 
liver development in LratCre Pdgfra-/- animals (see Section 1.5).  
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Future studies utilizing robust HSC isolation will also be needed in our current animal 
models as well as the prospective study mentioned above. HSC isolation will allow direct 
assessment of proliferative, migratory, and survival responses from HSCs isolated from Lrat-Cre 
Pdgfra-/- animals compared to littermate controls. Such studies would begin to clarify the distinct 
































HSCs α, ß  α, ß  α, ß  
(α, ß)  NR 
64, 66, 68, 69, 
77, 85, 87, 88 (Myofibroblast-specific) A, B, D** A, B, D (D) 
  










    
Kupffer Cells NR NR B NR NR 66, 96, 211 
Endothelial 
Cells α, ß  α, ß  α* α, ß A 






α  α  53, 66, 85, 87 
A, B**, C A, B**, C 
Bile Duct 
Epithelia - A, B, D D - A 
66, 99, 212, 214 
Platelets NR NR AB, C NR NR 98 
Infiltrating 
Macrophages NR NR A,B NR NR 
96, 211 
Table 1. Summary of PDGF and PDGFR isoform expression in select liver cells in normal and pathologic states. 
Key: A, B, C and D represent various PDGF ligands; α/β = PDGF receptors. Parentheses = expression specific to 
activated forms (myofibroblasts); NR = PDGF/PDGFR expression not reported in the evaluated literature; * = 






6.0  MATERIALS AND METHODS 
6.1 CELL CULTURE AND ASSAYS 
HHSteCs (Cat. # 5300, Lot # 10326) were purchased on two occasions from ScienCell Research 
Laboratories (Carlsbad, CA) and were cultured according to the company’s provided protocol. 
Cells were used prior to 6th passage to reduce culture activation of HSCs in vitro.  
6.1.1 Preparation and Cell Culture Treatments 
Cells were used prior to 6th passage and serum starved 12 hours prior to treatment by washing 
cells twice with sterile, cold PBS followed by serum-free Stellate Cell Medium (ScienCell). LX-2 
cells were provided by Dr. Scott Friedman (Mount Sinai, NY) and cultured according to protocol 
from commercial provider (Millipore, Billerica, MA). Cells were cultured/expanded in TPP-
treated T75 tissue culture flasks (Sigma-Aldrich, St. Louis, MO). Recombinant human PDGF-AA 
(R&D Systems, Minneapolis, MN) or PDGF-BB (Sigma), and TGFß1 (R&D Systems) was diluted 
with serum-free media and exposed to cells for the indicated time periods following two washes 
with sterile, cold PBS. For PDGFRα inhibition, PDGFRα-specific human monoclonal antibody 
inhibitor Olaratumab (LY3012207, IMC-3G3) or human IgG (Equitech, Kerrville, TX) was 
diluted in serum free media and used at the indicated concentrations following two washes with 
sterile, cold PBS. 
 111 
6.1.2 AlamarBlue Proliferation Assay 
For proliferation assays, HHSteCs were plated on 48-well plates (BD Falcon) at an initial plating 
density of 50,000 cells/well. Cells were serum starved the following day by gentle washing with 
chilled PBS followed by culturing in serum-free media overnight. Cells were treated the next day 
with serum-free media (NT), PDGF-AA, PDGF-BB, Olaratumab, or IgG at the indicated 
concentrations for 24 hours. Next, 20µl of AlamarBlue Cell Viability Reagent (Thermo Scientific) 
was added to each well and incubated at 37ºC for 1 hour before measuring fluorescence readings 
at 590nm wavelength.  Statistical analysis and graphs were performed in Prism Version 7.0a 
(GraphPad Software) using one-way and two-way ANOVA. 
6.1.3 Transwell Migration Assay 
All cells were serum starved for 12 hours prior to use in migration assays. Eight µm-pore 
polycarbonate filters (Costar) were pre-coated with 100µL collagen I (Sigma-Aldrich) and washed 
2 times with sterile PBS prior to adding cell suspension. Immediately prior to addition of cell 
suspension, Olaratumab, control IgG, or PDGF-BB were added to the lower chamber in serum free 
culture medium. HHSteCs were suspended in serum-free media and plated at 2000 cells in 
100µl/well. After incubation at 37°C for 3 hours, well inserts were fixed with 4% 
paraformaldehyde and stained by crystal violet. The number of migrated cells that was determined 
by counting the number of cells per representative 10X field by light microscopy. Statistical 
analysis and graphs were performed in Prism Version 7.0a (GraphPad Software) using non-





6.2 PROTEIN EXTRACTION AND WESTERN BLOTTING 
6.2.1 Whole Cell Lysate Preparation: Cell Lysates 
Whole cell lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer 
containing 1% IgePAL CA-630, 0.5% Sodium Deoxycholate, 0.1% Sodium dodecyl sulfate in 
Phosphate Buffered Saline (PBS). After adding protease/phosphatase inhibitor cocktail (Sigma 
Aldrich), 200 μl of RIPA was used per T-75 flaks (75 cm2). Lysates were centrifuged at 14,000 
RPM for 5 minutes at 4oC in order to remove clear supernatant to a new 1.5 ml tube while 
disposing of the pellet (non-soluble fraction). Samples were then stored at -80oC until utilization 
or protein concentration was measured via BCA protein assay (Pierce) to ensure equal protein 
concentrations for subsequent assays.  
6.2.2 Whole Cell Lysate Preparation: Liver Tissue 
At time of harvest, mice were anesthetized by isoflurane inhalation and subsequently killed by 
cervical dislocation. After sacrifice, the livers were extracted, washed in PBS, and then the tissue 
was flash frozen in liquid nitrogen and stored at -80oC until use. At time of use, tissue was 
homogenized in RIPA with protease/phosphatase inhibitor manually via glass mortar and pestle 
on ice. Lysates were removed to a fresh 1.5 ml tube and centrifuged at 14,000 RPM for 5 
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minutes at 4oC in order to remove clear supernatant to a new 1.5 ml tube while disposing of the 
pellet. Samples were then used for protein applications or stored at -80oC until utilization. 
6.2.3 Western Blot Analysis 
Western blots were performed on cell culture lysates homogenized in RIPA buffer with 
protease/phosphatase inhibitors (Thermo Scientific, Waltham, MA). Protein was quantified using 
bicinchoninic acid (BCA) protein assay and Western blotting was performed as previously 
described using commercially available primary antibodies from Santa Cruz Biotechnology 
(Dallas, TX) and Cell Signaling Technology (Danver, MA) outlined in Table 2 53. For HHSteC 
studies, Western blots from pooled samples from three technical replicates from each batch of 
stellate cells were performed at least twice. Representative Western blots from three pooled 
technical replicates for each timepoint are shown. Densitometry was performed on these 
representative Western blots. For detection of PDGFs in HHSteC media, media was concentrated 
after 24 or 48 hours of serum starvation using Amicon Ultra-15 Centrifugal Filters (Millipore) and 
resuspended in sample buffer prior to gel electrophoresis as previously described. 
6.2.4 Immunoprecipitation 
Co-immunoprecipitation studies were performed with 500μg protein lysate in RIPA buffer with 
protease/phosphatase inhibitors. 2µg of mouse monoclonal anti–CrkII (Santa Cruz Biotechnology) 
primary antibody was incubated with sample for 3 hours followed by overnight conjugation to 
Protein G PLUS-Agarose beads (Santa Cruz Biotechnology, sc-2002). Total and phospho-
PDGFRα was detected using the same antibodies indicated in Table 1. 
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6.3 RNA EXTRACTION AND SEMI-QUANTITATIVE REVERSE 
TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) 
RT-PCR was performed on RNA isolated using TRIzol (Thermo Scientific) RNA extraction from 
adherent cell cultures. Samples for each target were assessed as part of the same qPCR reaction 
and gel analysis. RNA extraction was performed using Direct-zol RNA MiniPrep Plus kit (Zymo 
Research, Irvine, CA) and following the manufacturer's protocol. Real time PCR was performed 
using Power SYBR Green (Thermo Scientific), 100 ng of cDNA, and 0.2 μmol/L of forward and 
reverse primers. Primers used in this study are listed in Table 3. Data was analyzed using the 
comparative ΔΔCt method or PCR product was run on 0.8% agarose gel with ethidium bromide 
and detected by UV lamp.  Statistical analysis and graphs were performed in Prism Version 7.0a 
(GraphPad Software, San Diego, CA) using one-way ANOVA. 
6.4 ANIMALS AND MODELS OF LIVER INJURY 
6.4.1 Mouse Model Development 
All animal experiments were performed under the guidelines of the National Institutes of Health 
and the Institutional Animal Use and Care Committee at the University of Pittsburgh. The 
studies performed in the current report were approved by the Institutional Animal Use and Care 
Committee at the University of Pittsburgh.  
For the generation of Pdgfra knockout strains, homozygous Pdgfra floxed (exons 1-4) 
were crossed with Foxa3-Cre, Alb-Cre or Lrat-Cre mice for the creation of F1 generation with 
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mice heterozygous for floxed Pdgfra as well as Cre allele. These mice were subsequently 
backcrossed with homozygous Pdgfra floxed mice to create Cre-positive homozygous floxed 
Pdgfra animals at a mendelian ratio of ¼. Lrat-Cre mice of a mixed background strain were 
provided by Dr. Robert Schwabe at Columbia University173. Foxa3- and Albumin-Cre mice and 
homozygous Pdgfra floxed (exons 1-4) were obtained from Jackson Laboratories (Bar Harbor, 
ME).  
6.4.2 Serum Liver Function Tests 
All liver function tests were performed by the UPMC Dept. of Pathology Division of Clinical 
Chemistry Automated Testing Laboratory.  
 
6.4.3 Carbon Tetrachloride 
Mice were injected intraperitoneally twice weekly with CCl4 (1:3 dilution in corn oil) at 0.5µl/g 
body weight for 4 weeks or 8 weeks. Animals were sacrificed 48 hours following last injection for 
liver and serum harvesting.  
6.4.4 Bile Duct Ligation Surgery 
In BDL, the peritoneal cavity is opened under anesthesia to expose the common bile duct and is 
cut between two 5-0 silk ligatures. Directly following surgery and at 24 and 48 hours post-surgery, 
mice were administered subcutaneous injection of 5mg/kg ketoprofen for analgesia. Livers and 
serum were collected at 5 days or 2 weeks post-BDL. These two timepoints were chosen to reflect 
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the differential contributions of portal fibroblasts and HSCs to the activated myofibroblast 
population at each of these times17. 
6.4.5 DDC Injury 
Animals were fed 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet ad libitum for 16 
days. Livers and serum were subsequently collected for analysis.  
6.5 IMAGE ANALYSIS 
6.5.1 Immunohistochemistry 
Liver tissue fixed for 48 hours in 10% formalin solution were embedded in paraffin and cut into 
4-micrometer sections for immunohistochemistry. Slides were deparaffinized in xylene and 
rehydrated in graded alcohol washes (100%, 95%, 70%) prior to dH20 washing. Heat-induced 
antigen retrieval was performed on sections by microwaving them for 12 minutes in citrate 
buffer (10mM sodium citrate + 0.05% Tween 20, pH6.0) (PCNA) or pressure cooking sections 
for 20 minutes in EDTA buffer (1mM EDTA + 0.05% Tween 20, pH9.0) (desmin, αSMA, CD45 
IHC). For F4/80 IHC, Proteinase K buffer (Millipore, Cat.#21627) was used for antigen retrieval. 
TUNEL was performed using ApopTag peroxidase kit (Millipore). 
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6.5.2 Immunofluorescence 
Liver tissue was fixed in 2% formaldehyde for 2 hours prior to 24 incubation in 30% sucrose 
solution. Following flash freezing in optimal cutting temperature (OCT) compound, tissue was cut 
in 6 micrometer thick sections and stored at -20ºC. For immunofluorescence staining, tissue was 
rehydrated with PBS followed by 10 minute detergent permeabilization using 0.1% Triton X-100 
in PBS. Next slides were incubated in dH20 for 30 minutes at 37ºC followed by blocking with 2% 
bovine serum albumin (BSA) in PBS for 45 minutes. Slides were incubated in primary antibody 
solution overnight at designated concentrations (Table 2) in 0.5% BSA in PBS (PBB). The 
following day, slides were washed with PBB prior to secondary antibody detection using species-
specific antibodies conjugated to Alexafluor 488 or Alexafluor 555 diluted 1:500 in PBB for 1 
hour. Slides were then washed sequentially with PBB and PBS followed by 30 second Hoeschst 
counterstain and slide covering. Epifluorescence images were obtained using a Nikon Eclipse Ti 
microscope and NIS Elements ver4.40. For confocal imaging, serially stacked, 1µm thick images 
were obtained using an Olympus FluoView 1000 microscope and FV1000 ASW ver. 4.2 software.  
6.5.3 Fibrosis Quantification 
Polarized light images of Picrosirius Red-stained liver sections were taken using an Olympus 
Provis microscope and MagnaFire software (ver. 2.1B). These images were quantified using NIS 
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αSMA Ms 42 -- -- 1:1000 
(IF) 
0.5% BSA Sigma C6198 
Akt Rb 60 1:1000 -- -- 5% BSA CST 4685 
P-S473-Akt  Rb 60 1:1000 -- -- 5% BSA CST 4060 
c-Abl Rb 135 1:1000 -- -- 5% BSA CST 2862 
P-Y89-c-Abl  Rb 135 1:1000 -- -- 5% BSA CST 3098 
P-c-Abl Y412 Rb 135 1:1000 -- -- 5% BSA CST 2865 
CD45 Rt 220 -- -- 1:100 PBS SCBT sc-53665 
CrkII Rb 42 1:1000 -- -- 5% BSA CST 3492 
P-Y221-CrkII  Ms 42 1:1000 -- -- 5% Milk CST 3491 
CrkL Rb 39 1:1000 -- -- 5% BSA CST 3182 
P-Y207-CrkL  Rb 39 1:1000 -- -- 5% BSA CST 3181 







Desmin Rb 52 -- -- 1:200  
(IF) 
0.5% BSA Thermo RB-9014 
E-Cadherin Rt 35 -- -- 1:500 
(IF) 
0.5% BSA BD Biosci BD610182 
Elk-1 Rb 47 1:1000 -- -- 5% BSA CST 9182 
P-S383 Elk-1 Rb 47 1:1000 -- -- 5% BSA CST 9181 
Erk1/2 Rb 42,44 1:1000 -- -- 5% BSA CST 4695 
P-T202/Y204-
Erk1/2  
Rb 42,44 1:1000 -- -- 5% BSA CST 4370 
F4/80 Rt 160 -- -- 1:200 
(IHC) 
PBS Bio-Rad MCA497GA 
FAK Rb 1
25 
1:1000 -- -- 5% BSA CST 13009 
P-Y397-FAK  Rb 125 1:1000 -- -- 5% BSA CST 8556 
P-Y576/577-
FAK  
Rb 125 1:1000 -- -- 5% BSA CST 3281 
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P-Y925-FAK  Rb 125 1:1000 -- -- 5% BSA CST 3284 
P-S2448-
mTOR  
Rb 289 1:500 -- -- 5% BSA CST 2971 
P-S2481-
mTOR  
Rb 289 1:1000 -- -- 5% BSA CST 2974 
p38 Rb 40 1:1000 -- -- 5% BSA CST 8690 
P-T180/Y182-
p38  
Rb 43 1:200 -- -- 5% Milk CST 4511 
PCNA Ms 29 -- -- 1:4000 
(IHC) 
PBS SCBT sc-56 
PDGF-A Ms 31 1:200 -- -- 5% Milk SCBT sc-9974 
PDGF-B Rb 14 1:1000 -- -- 5% Milk Abcam ab23914 
PDGF-C Gt 30 1:200 -- -- 3% BSA R&D Sys AF1560 
PDGF-D Gt 30 1:1000 -- -- 5% BSA R&D Sys AF1159 
PDGFRα Rb 190 1:1000  -- 5% BSA CST 3174 
PDGFRα  Gt 190 -- -- 1:40 
(IF) 
0.5% BSA R&D Sys AF1062 
PDGFRß Rb  1:1000 -- -- 5% BSA CST 3169 
P-Y572/574-
PDGFRα/ß  
Rb 190 1:1000 -- -- 5% BSA Invitrogen 44-1000G 
P-Y742-
PDGFRα  
Rb 190 1:1000 -- -- 5% BSA Invitrogen 44-1006 
P-Y762-
PDGFRα  




Rb 190 1:1000 -- -- 5% BSA CST 3170 
P-Y1018-
PDGFRα  





1:1000 -- -- 5% BSA CST 9371 
LYVE-1  35 -- -- 1:200 0.5% BSA Abcam Ab14917 
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Table 2. Primary Antibodies used for WB, IHC, IF, and IP. Abbreviations: CST – Cell Signaling Technology; Gt – 
goat; Ms – mouse; Rb – rabbit; Rt – rat; SCBT – Santa Cruz Biotechnology.  
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Primer Sequence (5’ to 3’) Amplicon 
(bp) 
ACTA2 Fwd TTC ATC GGG ATG GAG TCT GCT GG 141 
ACTA2 Rev TCG GTC GGC AAT GCC AGG GT 141 
COL1A1 Fwd TCG TCA CAG ATC ACG TCA TCG 120 
COL1A1 Rev AAT CAC CTG CGT ACA GAA CGG 120 
PDGFA Fwd CAC ACC TCC TCG CTG TAG TAT TTA 220 
PDGFA Rev GTT ATC GGT GTA AAT GTC ATC CAA 220 
PDGFB Fwd ACT CGA TCC GCT CCT TTG ATG A 111 
PDGFB Rev GCT CGC CTC CAG AGT GGG 111 
PDGFC Fwd TCA CAG CCC AAG GTT TCC TC 100 
PDGFC Rev CCA CAC CAG CGC CCT AAT AT 100 
PDGFD Fwd GAA CAG CTA CCC CAG GAA CC 100 
PDGFD Rev CTT GTG TCC ACA CCA TCG TC 100 
FN1 Fwd GGC TGA CAG AGA AGA TTC CCG AGA G 87 
FN1 Rev CCA GTT TAG ATG GAT CTT GGC AGA GAG 
AC 
87 
SYP Fwd GCA ATG GGT CTT CGC CAT CT 134 
SYP Rev GCC TGA AGG GGT ACT CGA AC 134 
TGFB1 Fwd CCC TGG ACA CCA ACT ATT GC 75 
TGFB1 Rev TGC GGA AGT CAA TGT ACA GC 75 
GAPDH Fwd GAA GGT GAA GGT CGG AGT C 226 
GAPDH Rev GAA GAT GGT GAT GGG ATT TC 226 
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